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ABSTRACT
Knowledge-based planning (KBP) techniques have been shown to provide
improvements in plan quality, consistency, and efficiency for advanced radiation
therapies such as volumetric modulated arc therapy (VMAT). While the potential clinical
benefits of KBP methods are generally well known, comparatively less is understood
regarding the impact of using these systems on resulting plan complexity and pretreatment quality assurance (QA) measurements, especially for in-house KBP systems.
Therefore, the overarching purpose of this work was to assess QA implications with
using an in-house KBP system and explore data-driven methods for mitigating
increased plan complexity and QA error rates without compromising dosimetric plan
quality. Specifically, this study evaluated differences in dose, complexity, and QA
outcomes between reference clinical plans and plans designed with a previously
established in-house KBP system. Further, a machine learning model – trained and
tested using a database of 500 previous VMAT treatment plans and QA measurements
– was developed to predict VMAT QA measurements based on selected mechanical
features of the plan. This model was deployed as a feedback mechanism within a
heuristic optimization algorithm designed to modify plan parameters (identified by the
machine learning model as important for accurately predicting QA outcomes) towards
improving the predicted delivery accuracy of the plan. While KBP plans achieved
average reductions of 6.4 Gy (p < 0.001) and 8.2 Gy (p < 0.001) in mean bladder and
rectum dose compared to reference clinical plans across thirty-one prostate patients,
significant (p < 0.05) increases in both complexity and QA measurement errors were
observed. A support vector machine (SVM) was developed – using a database of 500

xiv

previous VMAT plans – to predict gamma passing rates (GPRs; 3%/3mm percent dosedifference/distance-to-agreement with local normalization) based on selected
complexity features. A QA-based optimization algorithm was devised by utilizing the
SVM model to iteratively modify mechanical treatment features most commonly
associated with suboptimal GPRs. The feasibility was evaluated on 13 prostate VMAT
plans designed with an in-house KBP method. Using a maximum random leaf gap
displacement setting of 3 mm, predicted GPRs increased by an average of 1.14 ±
1.25% (p = 0.006) with minimal differences in dose and radiobiological metrics.
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1. INTRODUCTION
1.1.
1.1.1.

BACKGROUND
Radiation Therapy Treatment Delivery and Planning
Radiation therapy or radiotherapy involves the treatment of disease with the use

of high-energy radiation, which can take different forms such as x-rays, gamma rays,
electrons, and protons. The primary disease treated with radiation therapy is cancer,
with over half of all cancer patients receiving radiation therapy during the course of their
care.1 Typically, a cancer treatment team – comprising of physicians, physicists,
dosimetrists, therapists, and other healthcare professionals – works to plan, simulate,
test, and deliver a course of radiation therapy with the goal of simultaneously
maximizing cancer cell death and minimizing cell damage in surrounding healthy
tissues. This is an intricate process, marked by a plethora of treatment variables and
parameters that the treatment team must define in order to provide the patient with highquality radiotherapy.
One of the first choices that must be made is how to deliver the prescription dose
of radiation to the targeted disease. For photon radiotherapy, this dose can be delivered
either from outside of the patient or from directly within the patient. These two treatment
modalities are called external beam radiotherapy (EBRT) and brachytherapy. While
brachytherapy can present dosimetric and efficiency gains in specific treatment sites,
EBRT is the far more commonly used type of radiation therapy and will be the focus of
this work.2,3 Today, most courses of EBRT are delivered via a medical electron linear
accelerator (or LINAC), which generates a beam of Bremsstrahlung x-rays by
bombarding a tungsten target with electrons accelerated through a large potential
difference. These beams of x-rays are directed toward the patient and shaped
1

specifically to result in a dose distribution conforming to the target. Physical beam
blocks – such as collimating jaws and thin multi-leaf collimators (MLCs) in the head of
the LINAC or customized Cerrobend cutouts – can combine to shape the radiation
beam as desired by the treatment team. These LINAC features, among others, have
permitted the development of modern advanced radiotherapy delivery techniques.
Intensity modulated radiotherapy (IMRT) is a class of EBRT techniques defined
by the utilization of radiation fields with spatially varying fluence patterns. While
requiring more sophisticated software and hardware specifications, IMRT has been
shown to produce dose distributions with significantly improved target conformality,
healthy tissue sparing,4-6 and overall patient outcomes compared to non-modulated
delivery techniques (such as three dimensional conformal radiotherapy, or 3DCRT).7-9
While there are several specific implementations of using intensity modulated radiation
fields for treatment delivery, the two most common are fixed-gantry IMRT and
volumetric modulated arc therapy (VMAT). Fixed-gantry IMRT deliveries typically
employ five to seven fields of spatially varying fluence patterns of radiation spaced over
discrete angles around the patient. On the other hand, VMAT treatments involve the
continuous rotation of the LINAC gantry around the patient while delivering intensitymodulated segments of radiation at varying dose rates.10 Although the literature is
inconclusive regarding dosimetric superiority,11-16 the VMAT technique has been shown
to significantly increase treatment efficiency compared to fixed-gantry IMRT.17-23 VMAT
represents the latest technological advancement of rotational delivery techniques and
has become routine in clinical practice. Its clinical prevalence has even led some to
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debate whether its advantages will soon make conventional fixed-gantry IMRT
obsolete.24
In order to facilitate VMAT’s rise in clinical popularity, software innovations have
been necessary to take advantage of the hardware advances that enable a radiotherapy
delivery with modulated gantry rotation speeds, MLC positions, and dose rates.
Treatment planning systems (TPSs) are computerized applications that provide a virtual
environment for the treatment team to efficiently design and simulate a patient’s
treatment. A TPS models the physical treatment delivery devices (i.e. LINACs) and
provides an algorithm for calculating the radiation dose upon computed tomography
images of the patient’s anatomy. The general process of designing and evaluating
simulated treatments within such a system is referred to as treatment planning.
Treatment plans for VMAT deliveries must define hundreds of machine
parameters to instruct the LINAC control systems how to deliver the radiation for a given
patient. These parameters – notably the gantry speed, MLC leaf positions and speeds,
and dose rate – must be chosen in a way that combine to result in the desired dose
distribution. For simpler, non-modulated delivery techniques such as 3DCRT, a
“forward” planning technique is utilized whereby planning parameters are manually
defined and refined iteratively until the plan becomes clinically acceptable. Whereas for
more sophisticated delivery modalities like IMRT and VMAT, an “inverse” planning
approach – whereby the planner specifies the required clinical endpoints for each
patient after which an optimization algorithm searches for a feasible solution – is
required to efficiently determine clinically acceptable treatment plans.

3

Modern TPSs are equipped with these inverse optimization algorithms for
addressing the impractical challenge of manually defining those mechanical parameters
prior to dose calculation. As mentioned previously, the planner instead specifies arc
angles, target dose goals, and dose goals for sparing surrounding organs at risk (OARs)
so that an algorithm can heuristically search for a suitable set of intensity patterns and
mechanical specifications that achieve the stated dosimetric goals.25 If a planner wants
to improve the plan or assess clinical trade-offs, they must adjust the initial dosimetric
objectives and weights and run another optimization round followed by dose
computation. Represented as a numerical cost function to be minimized internally by the
TPS, deterministic and stochastic optimization methods are typically combined to
maximize the likelihood of finding a global – as opposed to local – minimum. However,
the existence of these sophisticated inverse planning algorithms still does not guarantee
a perfect or even clinically acceptable solution.25
Chief among the many factors limiting a planner’s ability to arrive at the best
treatment plan every time is the unique anatomy of each patient. Traditional planning
techniques do not provide planners any a priori information regarding what parameters
would result in the optimal plan for each patient. This limitation, along with the trial-anderror nature of inverse planning, causes the quality of inversely optimized plans to be
susceptible to planner bias, time constraints, and subjectivity. As a result, investigators
have observed numerous instances of variation in inverse treatment plan quality.26-31
Specifically, Nelms et al. found a wide variation in plan quality (defined in the study as
the ability of planners and plans to meet specified goals) among different treatment
planners and institutions.30 Interestingly, this finding was not statistically dependent on
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technologic parameters such as TPS and modality (i.e. fixed-gantry IMRT versus
VMAT) nor on planner demographics such as years of experience, certification, and
education. Although, Batumalai et al. found more experienced planners produced higher
quality head-and-neck IMRT plans.27 The authors instead suggest attributing the
variation in plan quality to planner “skill,” an undefined and potentially unquantifiable
term that underscores how inverse treatment planning can sometimes be more art than
science. To this end, researchers began investigating techniques for mitigating these
known deficiencies in traditional inverse planning.
1.1.2.

Knowledge-Based Planning
One such area of research is knowledge-based planning, or KBP. Although there

are many different categories and specific implementations, KBP systems generally
leverage retrospective anatomical and dosimetric patient data to guide the planning of
new patients. These data-driven approaches have been shown to improve the quality,
consistency, and efficiency of IMRT and VMAT planning compared to traditional
planning methods.32 Ge and Wu recently published a review article on KBP systems for
IMRT where they classified the different types of KBP implementations into six
categories based on the specific variables the models are designed to predict: (1) the
entire dose-volume histogram (DVH),33-64 (2) one or more dose metrics,45,65-75 (3) voxellevel dose,76-88 (4) objective function weights,45,89 (5) beam-related parameters (e.g.
number of beams, beam angles, and jaw settings),90-94 and (6) quality assurance (QA)
metrics.95-101 These specific categories can further be stratified into two major classes
according to their underlying mechanisms: (A) case or atlas-based methods and (B)
statistical modeling and machine learning methods.
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Whereas KBP methods in class (B) form predictive models (e.g. regression and
machine learning models) from an established database of previous patients, methods
in class (A) query the database for matches or “similar” cases and transfer selected
data to the new case. One such case-based technique was one of the first KBP
implementations investigated due primarily to its robustness and simple clinical
implementation. A seminal method was originally developed by Wu et al., where an
anatomical similarity metric is used to query a database of previous patients to predict
achievable dose-volume histogram objectives in IMRT planning.65 Specifically, the
similarity metric used to quantify patient anatomy is the overlap-volume histogram
(OVH).
The OVH, introduced by Kazhdan et al., is a shape relationship descriptor that
defines the distance at which fractional volumes of OARs lie from the target’s surface.102
More specifically, it is defined for a target T and organ O, where the value of the OVH of
O with respect to T at distance r is defined as the fractional organ volume a distance of r
or less from the target:
"#$!,# (&) =

|{+ ∈ "|-(+, /) ≤ &}|
|"|

where d(p,T) is the signed distance of a point p from the target’s boundary and |O| is the
volume of the OAR. An in-field OVH can be defined similarly for a structure O’, or the
portion of the organ O within the treatment fields. Such in-field volumes can be
estimated only considering voxels lying between the transverse planes 6 mm superior
and inferior to the most superior and inferior aspects of the planning target volume
(PTV) respectively (approximating the beam penumbra at depth). The in-field OVH has
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been found to produce improved bladder and rectum dose prediction accuracy for
VMAT prostate plans.103,104
As mentioned previously, the clinical viability of OVH-driven KBP methods has
been investigated due to the OVH’s robustness and its simple implementation.65,66,68,105
All of these methods assume that the dose received by a fractional OAR volume
depends on its proximity to the PTV, which is quantified by the OVH. Therefore, each
point of an OAR’s OVH can be mapped to one point of the corresponding DVH,
establishing a one-to-one relationship for each OAR of a given patient (Figure 1.1). This
one-to-one distance-to-dose mapping can be formed by relating a distance rv of an OVH
for a fractional OAR volume v to a dose-volume Dv of a DVH. This is the fundamental

PTV

OAR

OVH

DVH
Fractional Volume (%)

OAR

Fractional Overlap Volume (%)

principle for how the OVH is used to predict achievable DVH dose metrics.

100
v2
v1
0
-1 0 1 2 3 4
Distance

100

0

!!!

!!"

Dose

Figure 1.1. Graphic (adapted from Wu et al.) illustrating how the OVH is defined for two
example OARs and one PTV (left). It also shows the one-to-one relationship between
an OAR fractional volume’s distance from the target (OVH) and the dose it receives
(DVH), which is how OVHs are used to quantify patient anatomy for KBP dose-volume
prediction.105
Regardless of specific implementation, KBP methods have been observed to
contribute to overall improvements in OAR sparing and planning efficiency for several
treatment sites. For example, in Ge and Wu’s review of KBP approaches for prostate
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cancer, they found a mean reduction in bladder and rectum dose of 2.0 and 2.6 Gy,
respectively, across four different studies.32,51,55,59,103 Nevertheless, while reports of
these KBP methods leading to improved plan quality and planning efficiency are
encouraging, it is important to consider and investigate whether any clinical tradeoffs
arise incidental to these positive results.
1.1.3.

Plan Complexity
One potential consequence of improved plan quality is an increase in plan

complexity. As alluded to in Chapter 1.1.1, IMRT and VMAT have become the preferred
treatment delivery techniques for EBRT due to improved dose conformity to diseased
tissue and sparing of surrounding healthy tissue compared to traditional 3DCRT.
However, these techniques often result in increased beam modulation (i.e. complexity),
which has previously been described by the changes in MLC leaf positions, the number
of monitor units (MUs), the dosimetric uncertainty owing to losses in charged particle
equilibrium caused by smaller beam apertures, and the susceptibility to interplay
between the motions of the linear accelerator and internal organs.106-109
IMRT and VMAT plans require combinations of many irregularly shaped and
oftentimes small beam segments to obtain this increased dose conformity to target and
sparing of OARs. Small beam segments have higher degrees of dosimetric uncertainty
compared to traditional radiotherapies. This is primarily due to nonequilibrium conditions
created by secondary electron track lengths and source sizes being comparable to
small treatment field sizes, which results in increased beam penumbra.110 This
uncertainty places an emphasis on the TPS’s ability to accurately model lateral electron
scatter, MLC leaf ends, leaf transmission, and interleaf leakage for these plans. Among
several sources of error, plan complexity has been linked to the deliverability of IMRT
8

and VMAT plans, with increased complexity often leading to decreases in quality
assurance outcomes.111-113 Therefore, quantifying and reducing IMRT/VMAT plan
complexity is a reasonable strategy to improve deliverability.
Many different metrics have been established to quantify and describe plan
complexity. Simple characteristic plan parameters such as total MUs give quick firstorder indications about a plan’s complexity. But other metrics are typically classified as
fluence-based or aperture-based. More details on the complexity metrics used in this
work can be found in Appendix D.
1.1.4.

VMAT Quality Assurance
While VMAT is commonly available on modern commercial LINACs, the accurate

delivery of this sophisticated treatment technique requires precise synchronization of
MLC motion, gantry motion, and dose rate variations. Additionally, since continuous
VMAT arcs are approximated by many discrete segments (or static beams) during the
planning process, the delivery accuracy of VMAT treatments may depend on the
discretization resolution and plan complexity.114 This increase in plan complexity
(relative to non-modulated delivery techniques) underscores the clinical importance of
the QA process, which ensures IMRT treatment plans can be delivered as intended and
verifies the accuracy of the TPS dose computation. The current standard for VMAT QA
is to measure the planned radiation fields with a physical measurement device, and to
compare the result with that computed by the TPS.
This is typically done by copying the approved plan from the patient’s geometry
onto a water- or tissue-equivalent phantom with known specifications, upon which the
dose is then recomputed within the TPS. The plan is delivered to the QA phantom,
which contains one or more radiation detectors (typically diodes or ionization chambers)
9

to measure the dose (Figure 1.2). The agreement between the measured and
calculated dose is then evaluated, after which the plan is either approved for treatment
or rejected depending on the institution’s passing criteria.

Figure 1.2. This shows the typical setup for VMAT QA at our institution, where the
LINAC delivers the approved treatment plan to a known measurement device placed on
the couch.
Gamma analysis is one of the most prevalent methods utilized for comparing
computed and measured dose distributions in VMAT QA. Introduced by Low et al., the
gamma index is used to quantify both the percent dose-difference (%DD) and distanceto-agreement (DTA) between two dose distributions.115 Specifically, the gamma index g
is defined as,
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the dose difference, and ∆- and ∆: are the selected DTA and percent dose-difference
criteria respectively. g values equal to or less than one indicate that the comparison
passed with respect to the selected %DD and DTA gamma criteria, whereas values
greater than one indicate failure. The percent of points passing a given gamma criteria
is typically referred to as the gamma passing rate (GPR) and is commonly used as a
metric for quantifying the level of agreement between two dose distributions. Due to the
complex nature of IMRT treatments, this QA assessment is needed to check for errorfree data transfer, the accuracy of the TPS dose calculations, and the deliverability of
the plan on the treatment machine.114 Though there have been investigations into
software-based QA protocols,116-118 measurement-based techniques are still considered
the standard for QA.
A consequence of increased plan complexity is the potential for reducing the
accuracy of the delivered treatment, whereby the impact of uncertainties in relevant
delivery parameters – such as MLC leaf positions – are exacerbated by small,
irregularly shaped beam apertures and narrow leaf gap widths called for by the
treatment plan. For instance, Masi et al. found that increased VMAT plan complexity
(described by modulation complexity scores, or MCS, and leaf travel) was significantly
correlated with lower quality assurance outcomes.113 This reduced treatment delivery
accuracy can have clinical implications.113,119 These consequences have led
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investigators to explore strategies for quantifying and reducing plan complexity without
compromising plan quality.112,120,121
1.1.4.1.

Machine Learning for Patient-Specific Quality Assurance

Several investigators have applied machine learning models for predicting QA
outcomes based on treatment plan characteristics of fixed-gantry IMRT. Valdes et al.
were able to predict GPRs within 3% accuracy for IMRT plans using a generalized
Poisson regression model with Lasso regularization trained on a selection of 78 plan
complexity features.95,96 Interian et al. developed an ensemble of convolutional neural
networks trained to predict IMRT gamma passing rates from fluence maps with results
comparable to the Poisson regression model.97 More recently, Lam et al. used treebased machine learning algorithms to predict GPRs for portal dosimetry-based IMRT
beams with a mean absolute error of less than 1%.99 Such models can provide a priori
information regarding the deliverability of plans during the optimization stage, which
could provide many benefits that include minimizing wasted time in measuring and
adjusting treatment plans that are likely to fail QA.
While machine learning techniques have been primarily applied to fixed-gantry
IMRT QA, an evaluation of applying similar techniques for VMAT QA represents a
logical next progression. Granville et al. showed the feasibility of using machine learning
to classify results of VMAT QA measurements, where they trained a support vector
machine classifier to predict whether median dose differences between measured and
planned dose distributions were ‘hot’ (deviation more than 1%), ‘cold’ (deviation less
than -1%), or ‘normal’ (deviation within ±1%).122 Ono et al. used machine learning
models to predict GPRs on a specific QA measurement device using plan complexity
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features.101 These previous works show the feasibility of using machine learning
algorithms to accurately predict QA outcomes.
1.2.

MOTIVATION FOR RESEARCH
While the advantages of KBP techniques in treatment planning have been widely

described, the impact of their use on plan complexity and deliverability are less well
understood. Comparatively few studies have even reported on simple complexity
surrogates of KBP plans. Hussein et al. found no significant changes in MU and MCS
values of prostate IMRT plans when using a commercial KBP system (RapidPlan,
Varian Medical Systems, Palo Alto, CA).49 Likewise, Tamura et al. found no significant
changes in patient-specific quality assurance outcomes when using this commercial
KBP system.123 Conversely, Kubo et al. reported significantly increased MU values and
higher plan complexity when using the same commercial KBP system as the studies
noted previously.124 These results suggest that further assessment of the complexity
and deliverability of KBP-guided plans is needed. Therefore, the first purpose of this
study was to examine differences in dose, complexity, and quality assurance outcomes
between reference clinical plans and plans designed with an in-house KBP system.
Another objective of this work is to build upon existing literature for implementing
machine learning models for predicting VMAT QA outcomes. As mentioned in Chapter
1.1.4.1, previous investigators have shown this application of machine learning
algorithms to be feasible. However, each machine learning model is dependent on the
characteristics of the available data. In this particular application of machine learning,
each QA predictive model depends on the combination of technologies, the choice of
machine learning model, and clinical protocols used for optimizing VMAT treatment
plans, which can each vary across institutions. Therefore, the second purpose of this
13

work was to assess the feasibility of developing machine learning models for predicting
VMAT GPRs at our institution, which utilizes a different combination of technologies
(e.g. TPSs, delivery machines, and measurement devices) than previous works.
Further, another aim of this work is to explore and assess different machine learning
regression algorithms trained to predict gamma passing rates for VMAT QA from
treatment planning parameters and metrics.
Current TPSs have simple penalties to globally reduce complexity and for
controlling the likelihood of a plan failing VMAT QA. For example, the RayStation TPS
(v4.5.1.14; RaySearch Laboratories, Stockholm, Sweden) has one option to constrain
MLC leaf motion to a limited distance per degree of gantry rotation. Other works have
explored integrating other aperture-based penalties during optimization, where Younge
et al. were able to reduce complexity without degrading dose.112 However, these
penalties for reducing complexity do not guarantee a corresponding improvement in QA
outcomes given their moderate correlation; any potential impact on QA outcomes would
also be unknown until measurement. Investigators have consequently explored
methods – like machine learning – for predicting delivery accuracy for purposes of
identifying plans likely to fail QA prior to measurement. While these predictive models
may save time by flagging those at-risk plans, they are limited to the post-planning
stage. It would be ideal to actively optimize the treatment plans in terms of both doseand QA-based metrics. To our knowledge, such an optimization workflow has not been
investigated. Therefore, the third purpose of this work was to explore the feasibility of a
planning QA tool that directly optimizes QA outcomes without compromising plan
quality.
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1.3.

HYPOTHESES AND SPECIFIC AIMS
To this end, we hypothesized that KBP-guided plans result in significantly higher

complexity and reduced gamma passing rates (p < 0.05) compared to reference clinical
plans. Additionally, we hypothesize that a machine learning model designed to predict
VMAT QA gamma passing rates can be used in plan optimization to increase predicted
delivery accuracy without compromising KBP plan quality. In order to test these
hypotheses, three specific aims were developed for this study:
Aim 1.

Evaluate differences in plan complexity and delivery accuracy between
KBP and reference clinical plans of prostate cancer patients treated with
VMAT. Use four common metrics to describe overall plan complexity for
the VMAT plans and perform QA measurements to quantify differences in
delivery accuracy between the two sets of plans.

Aim 2.

Develop, test, and compare different machine learning models for
predicting gamma passing rates of VMAT QA measurements. Collect a
large set of plan data to train and test the models for establishing
performance.

Aim 3.

Develop and establish the feasibility of a planning QA tool. Deploy the
model from Aim 2 to interact with a commercial TPS to provide feedback
regarding the predicted QA outcome of the treatment plan during plan
optimization. Develop an in-house optimization algorithm to maximize
predicted delivery accuracy of inversely optimized treatment plans.
Demonstrate proof-of-concept on selected KBP plans.
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1.4.

OVERVIEW OF DISSERTATION
This document follows a manuscript-style dissertation format, where the main

chapters contain content derived from papers already published in or in preparation for
submission to peer-reviewed scientific journals. Below is a summary of these works and
their main contributions to the literature.
1.4.1.

Chapter 2: Evaluation of complexity and deliverability of prostate cancer
treatment plans designed with a knowledge-based VMAT planning technique
This chapter concerns the assessment of dosimetric, mechanical, and delivery

properties of plans designed with a common KBP method for prostate cases treated via
VMAT. Thirty-one prostate patients previously treated with VMAT were re-planned with
an in-house KBP method based on the overlap-volume histogram. VMAT plan
complexities of the KBP plans and the reference clinical plans were quantified via
monitor units, modulation complexity scores, the edge metric, and average leaf motion
per degree of gantry rotation. Each set of plans was delivered to the same diode-array
and agreement between computed and measured dose distributions was evaluated
using the gamma index. Varying percent dose-difference (1% to 3%) and distance-toagreement (1 mm to 3 mm) thresholds were assessed for gamma analyses. KBP plans
achieved average reductions of 6.4 Gy (p < 0.001) and 8.2 Gy (p < 0.001) in mean
bladder and rectum dose compared to reference plans, while maintaining clinically
acceptable target dose. However, KBP plans were significantly more complex than
reference plans in each evaluated metric (p < 0.001). KBP plans also showed significant
reductions (p < 0.05) in gamma passing rates at each evaluated criterion compared to
reference plans. While KBP plans had significantly reduced bladder and rectum dose,
they were significantly more complex and had significantly worse quality assurance
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outcomes than reference plans. These results suggest caution should be taken when
implementing an in-house KBP technique.
1.4.2.

Chapter 3: Application and comparison of machine learning models for
predicting quality assurance outcomes in radiation therapy treatment planning
This chapter describes the development and evaluation of machine learning

models for predicting QA outcomes of VMAT treatment plans. A dataset of 500 VMAT
treatment plans and diode-array QA measurements were collected for this study. GPRs
were computed using a 3%/3mm percent dose-difference and distance-to-agreement
gamma criterion with local normalization. 241 complexity metrics and plan parameters
were extracted from each treatment plan and their relative importance for accurately
predicting GPRs was assessed and compared using feature selection methods via
forests of Extra-Trees, mutual information, and linear regression. Hyperparameters of
different machine learning models – which included linear models, support vector
machines (SVMs), tree-based models, and neural networks – were tuned using crossvalidation on the training data (80%/20% training/testing split). Features were weakly
correlated with GPRs, with the small aperture score (SAS) at 50 mm having the largest
absolute Pearson correlation coefficient (0.38; p < 0.001). The SVM model, trained
using the 100 most important features selected using the linear regression method,
gave the lowest cross-validation testing mean absolute error of 3.75%. This represents
a significant 41.1% improvement (p < 0.001) over “random guessing” error as simulated
by randomly sampling a fitted normal distribution to the testing data. These predictive
models can help guide the plan optimization process to avoid solutions which are likely
to result in lower GPRs during QA.
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1.4.3.

Chapter 4: Use of machine learning algorithm during optimization to improve
patient-specific quality assurance in volumetric modulated arc therapy plans
This chapter assesses the feasibility of optimizing plan deliverability of VMAT

treatment plans using a machine learning model to predict QA outcomes. Current
inverse planning algorithms incorporate specific mechanical restrictions – such as
constraining leaf motion – that are designed to reduce the complexity of the treatment
plan. However, mechanical constraints do not guarantee a corresponding improvement
in measured QA outcomes. Therefore, this work explored the feasibility of an
optimization framework for directly maximizing predicted QA outcomes of plans without
compromising dosimetric quality. VMAT plans were retrospectively designed for 13
prostate patients using a previously established in-house KBP method. An SVM was
developed – using a database of 500 previous VMAT plans – to predict GPRs (3%/3mm
percent dose-difference/distance-to-agreement with local normalization) based on
selected complexity features. An optimization algorithm was devised by utilizing the
SVM model to iteratively modify mechanical treatment features most commonly
associated with suboptimal GPRs. Specifically, leaf gaps (LGs) less than 5 cm were
widened by random amounts, which impacts all aperture-based complexity features
such as small aperture scores and aperture area uniformity. The original 13 VMAT
plans were optimized with this QA-based algorithm using maximum LG displacements
of 1, 3, and 5 mm before corresponding changes in predicted GPRs and dose were
assessed. Predicted GPRs increased by an average of 0.30 ± 1.22% (p = 0.42), 1.14 ±
1.25% (p = 0.006), and 1.52 ± 1.27% (p =0.003) after QA-based optimization for 1, 3,
and 5 mm maximum random LG displacements, respectively. Differences in dose were
minimal, resulting in negligible changes in tumor control probability (maximum increase
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= 0.05%) and normal tissue complication probability (maximum decrease = 0.22%
among bladder, rectum, and femoral heads). A novel framework for optimizing predicted
GPRs was developed and shown to increase predicted QA outcomes without degrading
dosimetric quality of given plans. This method for integrating QA outcomes directly into
planning optimization could help improve the probability and efficiency of arriving at a
truly optimal treatment in terms of both dosimetric quality and QA outcomes.
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2. EVALUATION OF COMPLEXITY AND DELIVERABILITY OF
PROSTATE CANCER TREATMENT PLANS DESIGNED WITH A
KNOWLEDGE-BASED VMAT PLANNING TECHNIQUE
2.1.

PURPOSE
The purpose of this study was to evaluate differences in complexity and QA

outcomes between reference clinical VMAT plans for prostate cancer and those
designed with an in-house KBP method.
2.2.
2.2.1.

MATERIALS AND METHODS
Treatment Plans
A total of 31 prostate cancer patients previously treated at our institution were

used for the treatment planning in this study. Selected patients were originally
prescribed a dose to a single PTV and treated using two coplanar, 6 MV VMAT arcs.
The clinical plans were originally created using the current TPS at our institution
(Pinnacle3 v9.10, Philips Medical Systems, Fitchburg, WI, USA). For research purposes,
reference clinical plans were transferred or reconstructed in a research TPS
(RayStation v4.5.1.14, RaySearch Laboratories, Stockholm, Sweden), where our inhouse KBP method was developed. These reference clinical plans were re-computed or
re-optimized to approximate the original clinical plans (see Figure C.1 in Appendix C.1).
In addition to these reference clinical plans, a KBP-guided plan was generated
for each of the 31 patients using an in-house KBP technique. The KBP method, based
on OVHs incorporating fractional OAR volumes only within the treatment fields,was

Contents of this chapter were previously published as Wall PDH, Fontenot JD. Evaluation of complexity
and deliverability of prostate cancer treatment plans designed with a knowledge-based VMAT planning
technique. J Appl Clin Med Phys. 2020;21(1):69-77. Reprinted by permission of Wiley Periodicals, Inc.
(Appendix B.1)
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used to generate patient-specific bladder and rectum dose-volume predictions at the
10%, 30%, 50%, 65%, and 80% relative volume levels. These dose-volume predictions
were then input to the TPS as planning objectives and a KBP-guided plan was
optimized for each patient. Additional details of our KBP method are described
elsewhere103,125, but this OVH-guided KBP method was used in this study because it
can be easily implemented clinically and it has been previously shown to predict
achievable OAR dose-volumes.65,68,126 Moreover, it is useful to investigate these types
of in-house KBP systems for clinics that may not have the resources or ability to acquire
commercially available KBP systems.
A unique feature of this KBP method is that in addition to the manuallyconstructed clinical plans, the dose database was also populated with standardized
Pareto-optimal plans that equally weighted sparing of each OAR. When a dose-volume
was queried for patients with similar in-field OVHs to the new patient, the lowest dose
value among both the clinical and Pareto plans was selected as the new patient’s
predicted dose-volume. Our previous work showed the knowledge from the Pareto
plans often resulted in better achievable dose predictions.125 So it is important to
emphasize that the predicted dose-volume objectives from this KBP technique are
selected from the lowest dose values among the clinical and Pareto plans available in
the database.
It is also important to note that the KBP system is separate from the TPS
optimization engine, whereby the KBP algorithm predicts dose-volume objectives to
input into the TPS optimizer. For the KBP-guided plans, the planner strove to achieve
the bladder and rectum dose predictions along with originally prescribed physician goals
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for the target and remaining OARs. Once clinically acceptable target coverage was
achieved, OAR sparing was optimized until either the KBP dose predictions were
achieved or target coverage became clinically unacceptable.
Each set of 31 reference clinical plans and KBP plans were planned on the same
commercial TPS under the same planning conditions, which included the same planner,
machine, maximum leaf motion, dose grid resolution, and control point spacing. The
primary reason for reconstructing the reference clinical plans was to account for the
variations in these parameters that were used to design the original plans. Keeping
these parameters and other complexity mitigation tools constant for the reference plans
and KBP plans was desired in order to make the fairest comparison between these two
sets of plans. All plans were designed to be delivered on a commercial linear
accelerator equipped with a 160-leaf MLC (Infinity, Elekta AB, Stockholm, Sweden) and
were optimized with a maximum leaf motion of 7 mm per degree of gantry rotation
(mm/deg), dose grid resolution of 4 mm, and control point spacing of 4 degrees. Both
reference and KBP plans were optimized under the same conditions with the same
dosimetric endpoints for the target and OARs not including the bladder and rectum. The
only optimization differences between reference and KBP plans were the bladder and
rectum planning objectives, where reference plans utilized the original clinical goals and
KBP plans used the predicted dose-volumes from the KBP method as described
previously.
The plan quality of the reference plans and the KBP plans were compared
qualitatively with DVHs and quantitatively with Wilcoxon signed-rank tests on an array of
dose metrics at a significance level of p = 0.05.
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2.2.2.

Plan Complexity
The complexities of reference plans and KBP plans were quantified using the

total planned MUs, MCS113,120, the edge metric (EM)112, and the average MLC leaf
motion per degree of gantry rotation (LM). Planned MU values were normalized by the
fractional prescription dose to enable the comparison between plans of differing
prescriptions. The MCS was originally introduced by McNiven et al. to assess fixedgantry IMRT modulation complexity and was later adapted for VMAT by Masi et al.113,120
Briefly, the MCS is a metric ranging from zero (most modulated) to one (least
modulated) that incorporates leaf sequence variability and aperture area variability
components weighted by their segment contributions. The EM is computed as the
segment weighted ratio of in-field MLC side length and aperture area, which was
introduced by Younge et al. to characterize the amount of “edge” in apertures.112 The
values for the scaling factors used in this work were C1 = 0 and C2 = 1. LM was
determined by averaging the change in leaf position per degree of gantry rotation
calculated at each control point in the plan over each MLC leaf within the jaws.
These metrics were computed directly from the DICOM (Digital Imaging and
Communications in Medicine) RT Plan files using in-house software.127,128 MCS, EM,
and LM values of the reference and KBP plans were compared using two-sided paired
t-tests at a significance level of p = 0.05. Since the distribution of differences between
reference and KBP plan MUs did not meet the normality assumption of the t-test, a twosided paired Wilcoxon signed-rank test was used for comparing MUs.
2.2.3.

Delivery Accuracy
Each of the 31 reference and KBP plans were delivered on the commercial linear

accelerator platform for which it was planned (Infinity, Elekta AB, Stockholm, Sweden).
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Dosimetric measurements were performed using a commercial diode-array housed in a
water-equivalent phantom (MapCHECK2 and MapPHAN; Sun Nuclear Corporation,
Melbourne, FL, USA). Each set of plans was delivered on three separate occasions in
order to reduce effects of measurement noise and fluctuations. The diode array was
calibrated prior to each measurement session to eliminate the influence of daily
variations in machine output and detector response. While there are several other
dosimeters with their own advantages and disadvantages, such as film or EPID panels,
the MapCHECK2 was used in this study primarily to mimic the clinical protocol used at
our institution. Additionally, while film and EPID panels provide high spatial resolution
for relative measurements, they are not ideal absolute dosimeters. Detector arrays also
measure dose at detector locations more accurately than film due to processing and
densitometry uncertainties and are easier to use compared to film.114
Calculated dose distributions were generated for the measurement geometry and
plane by the TPS and were compared to measured data using gamma analysis in this
study as described in Chapter 1.1.4. Within gamma analysis, it is important to note the
role dose normalization plays in the %DD gamma criterion. Two possible normalizations
are global and local, where the former normalizes dose to the maximum dose in either
dose distribution and the latter normalizes dose to the dose at the local point being
evaluated. Typical tolerance limits are set as a percentage of points passing the given
gamma criteria (i.e. GPR). Task Group No. 218 (TG-218) recently recommended
tolerance and action limits for GPRs to be greater than or equal to 95% and 90%,
respectively, using a %DD/DTA gamma criterion of 3%/2mm with global
normalization.114
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Percent dose-difference and distance-to-agreement criteria of 3%/3mm,
2%/2mm, and 1%/1mm with both global and local normalization were used to evaluate
the agreement between the dose distributions. The 3%/2mm global criterion was
additionally examined to align with the recent recommendations for universal tolerance
and action limits from TG-218.114 Gamma passing rates were computed for each plan
using commercial quality assurance software (SNC Patient, Sun Nuclear Corporation,
Melbourne, FL, USA), where only points with dose above 10% of the maximum dose
were included in the analysis. The built-in calculated shift software feature was used to
account for setup uncertainties. Passing rates of the reference and KBP plans were
averaged over the three deliveries and statistically compared using two-sided paired ttests at a significance level of p = 0.05.
2.3.
2.3.1.

RESULTS
Plan Quality
Table 2.1 shows how reference plans compare statistically with KBP plans for an

array of DVH points and dose metrics. While KBP plans showed significant differences
in some PTV dose metrics compared to reference plans, it should be noted KBP PTV
doses were clinically acceptable and statistically equivalent to the original clinical PTV
doses. KBP plans showed significant (p < 0.001) decreases in bladder and rectum
doses compared to the reference plans. On average, Dmean for the bladder and rectum
was 6.4 Gy and 8.2 Gy lower for KBP plans compared to reference plans, respectively.
Average DVHs and the standard errors of the means are shown in Figure 2.1 for the
reference and KBP plans.
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Table 2.1. Statistical summary of dose values between reference and KBP plans.Note
that all doses were normalized so that 95% of the PTV received 76 Gy.
Wilcoxon
Means ± Standard Deviations
p-value
Dose Metric
Reference
Reference
KBP
vs.
KBP
PTV
D2 (Gy)
78.7 ± 0.9
79.2 ± 1.1
0.001*
D50 (Gy)
77.4 ± 0.5
77.7 ± 0.8
0.02*
D98 (Gy)
75.2 ± 0.9
74.8 ± 0.9
< 0.001*
Dmin (Gy)
67.1 ± 6.6
63.3 ± 7.0
< 0.001*
Dmean (Gy)
77.3 ± 0.5
77.6 ± 0.7
0.013*
Dmax (Gy)
79.6 ± 1.3
80.6 ± 1.5
< 0.001*
V95 (%)
99.7 ± 0.7
99.5 ± 0.8
< 0.001*
V98 (%)
99.0 ± 1.2
98.4 ± 1.2
0.77
V100 (%)
94.6 ± 2.3
94.8 ± 1.4
0.98
V107 (%)
0.02 ± 0.1
0.2 ± 0.5
0.011*
HI†
0.05 ± 0.02
0.06 ± 0.02
< 0.001*
CI†
1.4 ± 0.1
1.4 ± 0.06
0.002*
Bladder
D10 (Gy)
73.6 ± 6.1
68.4 ± 13.8
< 0.001*
D30 (Gy)
48.5 ± 18.7
38.2 ± 22.7
< 0.001*
D50 (Gy)
27.2 ± 18.5
19.5 ± 16.2
< 0.001*
D65 (Gy)
17.9 ± 15.7
11.6 ± 9.7
< 0.001*
D80 (Gy)
12.5 ± 13.0
7.7 ± 6.5
< 0.001*
Dmean (Gy)
35.1 ± 12.8
28.6 ± 12.0
< 0.001*
Rectum
D10 (Gy)
72.8 ± 4.6
69.1 ± 7.9
< 0.001*
D30 (Gy)
51.4 ± 12.1
39.8 ± 17.0
< 0.001*
D50 (Gy)
35.4 ± 12.8
21.9 ± 12.9
< 0.001*
D65 (Gy)
24.6 ± 12.9
13.8 ± 9.0
< 0.001*
D80 (Gy)
15.0± 11.9
8.9 ± 6.5
< 0.001*
Dmean (Gy)
38.0 ± 8.9
29.8 ± 9.3
< 0.001*
Left Femoral Head
D2 (Gy)
40.1 ± 6.7
40.4 ± 7.1
0.019*
Dmax (Gy)
45.9 ± 10.4
47.8 ± 10.2
< 0.001*
Dmean (Gy)
26.6 ±5.1
26.1 ± 5.6
0.95
Right Femoral Head
D2 (Gy)
39.5 ± 6.8
40.5 ± 7.7
< 0.001*
Dmax (Gy)
44.8 ± 9.8
47.0 ± 9.3
< 0.001*
Dmean (Gy)
26.8 ± 5.1
26.6 ± 6.0
0.65

(table cont’d)
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Means ± Standard Deviations
Dose Metric
Reference
Penile Bulb
Dmean (Gy)

35.5 ± 18.4

KBP
34.9 ± 18.9

Wilcoxon
p-value
Reference
vs.
KBP
0.18

*Indicates a statistically significant result of p < 0.05
†
Homogeneity and conformity indices were calculated according to their International
Commission on Radiation Units & Measurements definitions.

2.3.2.

Plan Complexity
KBP plans were significantly more complex than reference plans in every

evaluated metric. On average, KBP plans required 143 more MUs (p < 0.001), had
reduced MCS values of 18% (p < 0.001; indicating increased complexity), had 40%
higher EM values (p < 0.001), and 47% higher LM (p < 0.001) compared to reference
plans (Table 2.2).
Table 2.2. Statistical summary of the differences in complexity metrics between the
reference and KBP plans.
Complexity Metric

Reference Plans
(@ ± !)

KBP Re-plans
(@ ± !)

t-test
p-value

MU

450 ± 83

593 ± 113

< 0.001*†

MCS

0.5 ± 0.1

0.4 ± 0.1

< 0.001*

EM

0.06 ± 0.02

0.08 ± 0.01

< 0.001*

LM (mm/deg)

1.0 ± 0.6

1.5 ± 0.5

< 0.001*

*Indicates a statistically significant result of p < 0.05
†
Result from two-sided Wilcoxon signed-rank test because the distribution of differences in MUs
between reference and KBP plans was determined to break the t-test assumption of normality.

Complexity metrics were shown to be strongly correlated with each other. An
increase in MUs correlated with more complex MCS, EM, and LM values with Pearson
correlation coefficients (R) of -0.85 (p < 0.001), 0.91 (p < 0.001), and 0.84 (p < 0.001)
respectively. Similarly, an increase in complexity in terms of the MCS score correlated
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strongly with an increase in EM values (R = -0.94; p < 0.001) and LM (R = -0.88; p <
0.001). Lastly, an increase in EM values corresponded strongly with more LM with R =
0.85 (p < 0.001).

Figure 2.1. Average DVHs comparing reference clinical plans (solid) and KBP plans
(dashed) for the 31 patients of each labelled planning structure (a-f). The standard error
of the means is also included as filled bands with solid (reference) or dashed (KBP)
edge lines. Note that doses were normalized so that 95% of the PTV received 76 Gy.
2.3.3.

Delivery Accuracy
KBP plans showed significant reductions in quality assurance outcomes

compared to reference plans as described by gamma passing rates. For criteria with
global normalization, KBP plans on average had gamma passing rates that were 1.1,
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1.6, 3.8, and 7.8 percentage points lower than reference plans at the 3%/3mm (p =
0.009), 3%/2mm (p = 0.003), 2%/2mm (p = 0.002), and 1%/1mm (p < 0.001) criteria
respectively. Significant reductions in KBP plan gamma passing rates compared to the
reference plans were also observed at each evaluated gamma criteria using local
normalization (Table 2.3). Additionally, it is notable that KBP plans showed significantly
greater inter-delivery variations (p < 0.05) in gamma passing rates than reference plans
at each gamma criteria for both global and normalization methods (Table C.1).

Local

Global

Table 2.3. Statistical summary of the differences in gamma passing rates between the
reference and KBP plans at different gamma criteria.
Gamma
Criteria

Reference Plans
Gamma Pass Rates
(@ ± !)

KBP Plans
Gamma Pass Rates
(@ ± !)

3%/3mm

98.8 ± 1.3

97.7 ± 2.5

0.009*

3%/2mm

98.3 ± 1.7

96.6 ± 3.3

0.003*

2%/2mm

93.8 ± 4.2

90.0 ± 6.8

0.002*

1%/1mm

69.7 ± 8.7

61.9 ± 11.7

< 0.001*

3%/3mm

91.8 ± 4.4

88.9 ± 6.6

0.03*

2%/2mm

87.4 ± 6.0

82.0 ± 9.5

0.003*

1%/1mm

75.4 ± 8.7

66.5 ± 11.9

t-test
p-value

< 0.001*

*Indicates a statistically significant result of p < 0.05

Patient-specific QA outcomes at the 3%/3mm global gamma criterion for all
reference plans were greater than 95%. As for the KBP plans, only two plans had
passing rates of less than 95% but greater than 90%. One KBP plan had a gamma
passing rate of lower than 90% (87.7%).
Gamma passing rates were also found to be weakly to moderately correlated
with the evaluated plan complexity metrics (Table 2.4). For instance, gamma passing
rates at the 2%/2mm local criterion moderately correlated with MUs (R = -0.47; p <
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0.001), MCS values (R = 0.42; p < 0.001), EM values (R = -0.40; p = 0.001), and LM (R
= -0.37; p = 0.003).
Table 2.4. Pearson correlation coefficients between complexity metrics and gamma
passing rates.
Pearson Correlation Coefficients (p-value)

Local

Global

Gamma
Criteria

MU

MCS

Edge Metric

Leaf Motion

3%/3mm

-0.37 (0.003*)

0.36 (0.004*)

-0.36 (0.004*)

-0.33 (0.009*)

3%/2mm

-0.43 (< 0.001*)

0.40 (0.001*)

-0.40 (0.001*)

-0.38 (0.002*)

2%/2mm

-0.45 (< 0.001*)

0.39 (0.002*)

-0.39 (0.002*)

-0.36 (0.005*)

1%/1mm

-0.50 (< 0.001*)

0.45 (< 0.001*)

-0.46 (< 0.001*)

-0.40 (0.001*)

3%/3mm

-0.35 (0.006*)

0.31 (0.02*)

-0.29 (0.02*)

-0.21 (0.10)

2%/2mm

-0.47 (< 0.001*)

0.42 (< 0.001*)

-0.40 (0.001*)

-0.37 (0.003*)

1%/1mm

-0.56 (< 0.001*)

0.50 (< 0.001*)

-0.50 (< 0.001*)

-0.49 (< 0.001*)

*Indicates a statistically significant result of p < 0.05

2.4.

DISCUSSION
In this work, VMAT plans for prostate cancer patients designed with an OVH-

guided KBP method were significantly more complex and had significantly lower patientspecific quality assurance outcomes compared to manually-constructed reference
plans. While KBP-guided plans led to significant improvements in OAR sparing, the
values of MU, MCS, EM, and LM were all significantly more complex. In addition, a
weak to moderate correlation was observed between the analyzed complexity metrics
and quality assurance outcomes.
To our knowledge, this work is the first evaluation of plan complexity and
deliverability of plans derived from an OVH-guided KBP method, whereas other studies
have reported results from the commercial KBP product, RapidPlan. The observed
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improvements in KBP plan quality are consistent with previous studies investigating
KBP methods for prostate cancer.67,76 The OAR dose-volume predictions generated
from the OVH-guided KBP model are designed to output the lowest achievable dose
levels based on previous data. The results from this study indicate that the achievability
of these predictions seem to come at the cost of significant increases in plan
complexity, which is consistent with the work of Kubo et al.124 On the other hand,
Tamura et al. reported KBP plans to have similar complexity to reference plans overall.
They also observed significantly reduced (p < 0.05) leaf travel in KBP plans. Both
Tamura et al. and Kubo et al. each evaluated 30 prostate patients using the same
commercial KBP system. It is worth highlighting the differences between the KBP
method used in the present study and the commercial system (RapidPlan) used in
these previous studies. Whereas the RapidPlan training algorithm uses model-based
principal component regression129, the KBP system in this work follows an established
library lookup algorithm to find the lowest dose achieved among a database of
previously treated patients with similar in-field OVHs to the new patient.126 Also, as
mentioned previously in Chapter 2.2.1, standardized Pareto-optimal plans were added
to the dose database and were found to further improve OAR sparing overall compared
to using data from manually-constructed clinical plans.125 This distinguishes this OVHdriven KBP system from RapidPlan’s regression-model technique. Therefore, one
possible explanation for this discrepancy among previous works could be the
differences in dose objectives and resulting distributions, i.e., the extent to which one
study more aggressively pursued a better plan result than the other. Further, the
differences between previous findings and our results may be explained by the differing
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KBP techniques and also differences in the quality of the underlying dose databases
these KBP systems used to generate their dose objectives. While KBP plans in both
previous studies achieved similar dose to clinical plans overall, KBP plans reported by
Kubo et al. showed significantly lower mean bladder dose along with significantly higher
MUs and more complex MCS values. Our study achieved similar bladder dose
reductions as Kubo et al. These results therefore suggest the possibility that increased
complexity may be required in order to meet the “ideal” dose objectives, in which case
efforts to mitigate complexity may reduce the quality of the KBP-guided dose
distributions.
We did not observe a strong correlation between improved bladder mean dose
and increased complexity and only a moderate (R ≥ 0.48) correlation between improved
rectum mean dose and increased complexity (Figure C.4). Plan complexity metrics were
also not strongly correlated with gamma passing rates. This observation is consistent
with previous works113,130 and could indicate the selected plan quality metrics cannot
fully describe plan complexity, even though available evidence suggests a relationship
does exist. While there have been studies showing increased monitor units are
necessary for achieving desired dose distributions for certain IMRT cases with complex
geometry131, other studies have observed instances of unnecessary VMAT plan
complexity and were able to reduce complexity without substantially impacting plan
quality using complexity penalties.112 As Mohan et al. noted, the amount of possible
complexity reduction is dependent on the difficulty of the underlying treatment
plan.131,132 However, it remains uncertain whether the increased complexity observed in
the KBP plans of this study was required for the improved OAR dose. Further
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investigation into what extent the complexity of these KBP plans could be mitigated by
exploring different TPS optimization settings is warranted.
The clinical implications of increased plan complexity and reduced delivery
accuracy have been studied extensively, which served as a primary motivation for this
study. Investigators such as Younge et al. have implemented aperture complexity
penalties into the plan optimization stage to limit plan complexity without degrading plan
quality.112 Others have examined how an array of metrics that quantify beam complexity
(such as leaf travel in addition to plan irregularity and modulation) correlate with delivery
accuracy and pre-treatment verification results.119,121 Valdes et al. recently showed the
feasibility of using machine learning techniques to accurately predict gamma passing
rates of IMRT plans using many complexity features.95,96 It is possible that further
accounting for plan complexity using these similar methods during the optimization
stage could reduce KBP’s observed impact on complexity on a plan-specific level,
thereby providing a more accurate delivery. This is an avenue of research we plan on
investigating in future work.
This study had several limitations. Planning time was not explicitly recorded in
this research since KBP has been extensively shown to improve planning
efficiency.44,46,52,53 However, average KBP planning time was qualitatively comparable
to average reference planning time in the present study. Also, standard clinical values
for control point spacing and dose grid resolution were used in this work. While it is
possible increasing the resolution of these two parameters could mitigate the observed
differences in calculated and measured KBP dose113, the settings used in this study
have been shown to provide an acceptable balance of calculation accuracy and
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speed.133,134 Also, the leaf motion was not constrained beyond the default limits of the
modeled linear accelerator. It is possible that adjusting these specific optimization
parameters may diminish KBP plan complexity and delivery accuracy deficiencies to an
extent.135-137 Another potential limitation is that only a limited number of metrics where
chosen to quantify plan complexity, though the chosen metrics are commonly used in
the literature.113,121
The use of a diode-array also presents potential limitations. A previous study
have observed a slight temperature dependence for individual MapCHECK diodes
ranging from 0.52% to 0.57%/°C.138 The impact of any existing temperature
dependence would likely be negligible in the present study as the measurements for
KBP and reference plans were acquired consecutively and in temperature-controlled
rooms. Also, other studies have shown an angular dependence to be the factor that
most affects the accuracy of MapCHECK2 measurements – particularly at gantry angles
of 90 and 270 degrees – which could potentially affect gamma passing rates.139,140
While this study did not directly investigate the effects on these temperature and
angular dependencies on delivery accuracy, the gamma passing rates at clinicallyrelevant criterion for the plans in this study were consistent with those observed at our
clinic for prostate cases. Additionally, the commercial diode array used in this work has
been shown to provide accurate VMAT QA measurements despite this angular
dependence.140-142 It is also important to note the results seen here with this specific
combination of technologies (OVH-guided KBP method, RayStation TPS, Elekta
treatment machine, and MapCHECK2 diode array) may not hold for different KBP
methods and planning, delivery, and measurement technologies as evidenced by the
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results from Tamura et al.123 Regardless, the results of this study indicate that caution is
needed regarding the effects of plan complexity and quality assurance outcomes when
implementing any KBP system as they become more clinically prevalent. However,
these results supplement the available literature showing KBP’s potential in providing
immediate and substantial clinical impact. In-house OVH-guided KBP systems similar to
the one described in this work could be developed and implemented clinically without
disrupting the existing inverse optimization workflow. The KBP system would provide
patient-specific predicted bladder and rectum dose-volume planning objectives prior to
planning, and the planner could then strive to meet these KBP goals as they would
normally. The observed increase in complexity and reduction in QA outcomes from this
study may warrant additional focus on the quality control of KBP plan delivery. The
qualified medical physicist would be responsible for monitoring the deliverability of
VMAT plans designed with any KBP system. Provided that any reduction in QA
outcomes does not result in consistently unacceptable plans, the substantial potential
improvement in plan quality provided by KBP systems should persuade the clinical
physicist to investigate the feasibility of implementing a KBP system within his or her
institution.
Our study did not investigate the source of the reduced quality assurance
outcomes of KBP-guided plans. While it would certainly be important and desirable to
characterize the specific causes of delivery accuracy discrepancies between KBP and
reference plans we leave this for future research as it lies outside the scope and
purpose of the current work. However, there are known categories of uncertainties in
the IMRT planning and delivery process that include: limitations of the beam model (e.g.
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MLC modeling, modeling output factors for small fields, etc.), mechanical and dosimetric
uncertainties of the delivery system (e.g. MLC leaf position and speed errors, gantry
rotation and table motion stability, beam stability, etc.), and measurement and analysis
uncertainties (e.g. setup errors).114 Given evidence available in the literature, the
primary source of error in the discrepancies between KBP and reference GPRs is most
likely inaccuracies in the TPS dose computation. For instance, Masi et al. observed
increased GPRs with plans optimized with a finer control point spacing compared to
plans of similar complexity optimized with a courser control point spacing.113 Therefore,
since the KBP and reference plans were optimized under the same TPS settings, the
resulting differences in GPRs may primarily be caused by limitations in the TPS’s ability
to accurately model and compute dose of plans of higher complexity. Increasing the
control point spacing resolution during KBP plan optimization could mitigate the
observed delivery errors to some extent, but future work is needed to fully describe the
specific sources of error. KBP effects on plan complexity and gamma passing rates for
different treatment sites, such as the head and neck, would also be instructive to
explore. But overall, this research gives reason to further validate and verify all aspects
of the treatment workflow when implementing KBP systems, whether they be
established in-house or commercially available methods.
2.5.

CONCLUSION
While KBP methods have been shown to improve the quality and consistency of

treatment plans across institutions, the results of this study suggest their use can
significantly increase plan complexity and reduce patient-specific QA outcomes. An infield OVH-guided KBP method was used to generate 31 VMAT plans for previous
prostate cancer patients. KBP plans showed significantly reduced bladder and rectum
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dose but were significantly more complex compared to reference plans. The KBP plans
showed a significant reduction in delivery accuracy - as measured by patient-specific
QA measurements. These results demonstrate that care should be taken when
implementing KBP models to ensure resulting plans achieve acceptable quality and
deliverability.
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3. APPLICATION AND COMPARISON OF MACHINE LEARNING
MODELS FOR PREDICTING QUALITY ASSURANCE OUTCOMES IN
RADIATION THERAPY TREATMENT PLANNING
3.1.

PURPOSE
The purpose of this study was to develop, validate, and compare different

machine learning models for predicting quality assurance outcomes of VMAT treatment
plans.
3.2.
3.2.1.

MATERIALS AND METHODS
Data
This study was approved by the Institutional Review Board at Louisiana State

University under IRB# E11428 (see Appendix A). In total, 500 dataset samples were
collected and anonymized from patients who were previously treated with VMAT at our
institution. The specific data collected from each patient case consisted of the following:
the DICOM RT-Plan file, containing the technical parameters of the clinically approved
treatment plan; the QA measurement file, containing the measured dose acquired
during QA; and the predicted QA dose output from the TPS. The inclusion criteria for
each sampled case required each patient to have been previously treated with at least
one VMAT arc and the subsequent QA measurement to have been performed with a
MapCHECK2 diode-array housed in a MapPHAN water-equivalent phantom (Sun
Nuclear Corporation, Melbourne, FL, USA). The diode-array was calibrated prior to
each measurement to eliminate the influence of daily variations in machine output and

Contents of this chapter were previously published as Wall PDH, Fontenot JD. Application and
comparison of machine learning models for predicting quality assurance outcomes in radiation therapy
treatment planning. Informatics in Medicine Unlocked. 2020;18:100292. Reprinted by permission of
Elsevier Ltd. (Appendix B.2)
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detector response. All treatment plans were designed using Pinnacle3 (v9.10, Philips
Healthcare, Amsterdam, Netherlands) and delivered using one of four matched Elekta
linear accelerators equipped with Agility MLC heads (Elekta AB, Stockholm, Sweden).
3.2.1.1.

Features

Treatment plan parameters and characteristics were extracted from the DICOM
RT-Plan file of each sample using in-house software. These parameters were used to
formulate an array of features that would later be used to develop machine learning
regression models for predicting QA outcomes. This consisted of 241 raw features,
which can be categorized into the 23 groups of treatment plan parameters and
complexity metrics listed in Table 3.1.
Table 3.1. Summary of 23 feature groups assembled for this study.
Feature Group
Reference(s)
Notes
Modulation
McNiven et
Complexity Score
al.120 and Masi
–
(MCS)
et al.113
Edge Metric (EM)
Younge et al.112
–
Total leaf travel per leaf; includes 1st, 2nd, 3rd,
Leaf Travel (LT)
–
4th, and 5th moments unweighted and
weighted by segment MU

Leaf Motion (LM)

–

Arc Length

–

MU Factor

–

Number of Arcs
Average Jaw
Position (JP)
Jaw Travel (JT)

–

Average Jaw
Motion (JM)

–
–
–

Defined as average leaf travel per degree of
gantry rotation; includes 1st, 2nd, 3rd, 4th, and
5th moments unweighted and weighted by
segment MU
Total degrees of gantry rotation in plan
Total planned MUs normalized by fractional
dose to specification point
Feature for each jaw and feature with
average combined jaw position
Total travel for each jaw
Average jaw travel per degree of gantry
rotation for each jaw; unweighted and
weighted

(table cont’d)
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Feature Group
Average
collimator angle
Aperture Area
(AA)
Aperture
Perimeter (AP)
Plan Irregularity
(PI)
Leaf Gap (LG)
Plan Modulation
(PM)
Small Aperture
Score (SAS)
Cross-axis Score
(CAS)
Fractional Area
Outside of Circle
(FAOC)
Nominal Dose
Rate
Treatment
Machine
Treatment Site
Flattening Filter
Free (FFF)

Reference(s)

Notes

–

–

Du et al.143
Du et al.143
Du et al.143
–

1st, 2nd, 3rd, 4th, and 5th moments unweighted
and weighted by segment MU
1st, 2nd, 3rd, 4th, and 5th moments unweighted
and weighted by segment MU
1st, 2nd, 3rd, 4th, and 5th moments unweighted
and weighted by segment MU
Distance between opposing in-field leaf
pairs; 1st, 2nd, 3rd, 4th, and 5th moments
unweighted and weighted by segment MU

Du et al.143
Crowe et al.144

–
Additional feature included maximum SAS
among all control points

Crowe et al.144

–

Valdes et al.95

1st, 2nd, 3rd, 4th, and 5th moments unweighted
and weighted by segment MU

–

–

–
–

One of four dosimetrically matched
machines
–

–

–

Three of these feature groups include the following categorical features: (1) the
specific treatment machine on which the plan was delivered, (2) the treated anatomical
site, and (3) the use of a specialized high-dose delivery mode. In sum, 29 abdomen, 13
breast, 36 chest, 13 chest wall, 148 head and neck, 127 lung, 61 prostate, 30 prostatic
fossa, 32 pelvis, and 11 miscellaneous (knee, spine, and shoulder) treatment plans
were collected for this study. The remaining 20 feature groups were numerical and
derived from complexity features found in the literature. For groups characterized by
distributions, features such as mean, standard deviation, and up to the 5th moment
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about the mean were extracted. Features were also implemented with and without
accounting for segment MU weightings where applicable.
3.2.1.2.

Target Values

GPRs were computed using in-house software from each sample’s predicted QA
dose file from the TPS and the measured dose from performing the QA. The software
was modified from existing open-source code for computing the gamma index to
interface with the input data and to include a feature accounting for setup errors . Setup
errors were mitigated by shifting the planned dose distribution in 1 mm steps along the
cardinal axes within a 10 mm radius to search for better agreement. The foundation of
the computation algorithm and validation procedure was based on previous work.145
The gamma index for each point was computed with a percent dose-difference criterion
of 3%, a distance-to-agreement criterion of 3 mm, local normalization, and a 10% dose
threshold.
3.2.1.3.

Data Processing

In order to avoid data snooping bias in the development and evaluation of
machine learning models, the overall dataset was split into a training set and a testing
set with 400 and 100 samples respectively (i.e. 80%/20% split). Data was split using a
stratified technique based on the distribution of GPRs to guarantee the testing set be
representative of the overall population of GPRs. Figure 3.1 shows the differences in
random and stratified sampling for splitting the data, where the standard randomized
technique resulted in a test set distribution that was less representative of the total
distribution compared to the stratified technique. This is particularly pronounced when
comparing the standard deviation of the two testing set distributions against that of the
overall distribution in the Figure 3.1 example. The overall GPR distribution of the
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dataset had a standard deviation of 6.01%, compared to 6.13% and 5.49% for the
testing sets resulting from a stratified and random sampling, respectively. Therefore, the
stratified sampling avoids possible sampling bias in the target variable by generating
training and testing sets with target distributions representative of the overall dataset
distribution.

Figure 3.1. Histograms of GPR distributions for the entire dataset (blue), training set
(orange), and testing set (green) when utilizing a random (left) and stratified (right)
sampling technique. The stratified technique provides training and testing sets with GPR
distributions sampled proportionally from the entire dataset, which avoids bias from
over- or under-sampling certain ranges of GPRs as seen with the purely randomized
technique.
After splitting the data, categorical features were one-hot encoded to represent
every category in each feature group as a binary attribute. Feature standardization was
applied to numerical features, where the mean value was subtracted and the variance
normalized to one. This transformation was fit to the training data and was then applied
to the testing set i.e. the testing set data was not used in the initial standardization
process.
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3.2.2.

Feature Analysis and Selection
Feature selection is a process used in developing machine learning models that

can have several benefits. Selecting a subset of the most important features can
simplify interpretation and visualization of the data, reduce training and utilization times,
or improve the overall performance and robustness of the predictive model.146 In this
study, each feature’s relative importance in contributing to the accurate prediction of
GPRs was quantified and ranked using three different methods: forests of extremely
randomized decision trees (Extra-Trees), mutual information, and linear regression.
Decision Trees are a powerful machine learning algorithm that work to search for
the feature and the decision threshold within that feature that best splits the training
data into similar response categories. More specifically, the feature and decision cutpoint for each node of a Decision Tree is determined such that the cost function – e.g.
mean squared error (MSE) between the predicted output and the true value – is
minimized. Decision Trees are formed deterministically and typically employ a greedy
training algorithm, where the optimum split is searched for at each decision node. While
classical Decision Trees are versatile machine learning algorithms and capable of fitting
complex datasets, they can suffer from overfitting the training data.
Random Forests are another class of tree-based algorithms developed in an
effort to reduce model variance found with regular decision trees.147 A Random Forest is
an ensemble of Decision Trees that grows its trees by searching for the best feature
among a random subset of features. Random Forests are a bagging technique, where a
collection of estimators is trained on different random subsets of the training set with
replacement. Once all of the estimators are trained, the Random Forest ensemble
aggregates all estimator predictions by averaging them. Generally, the random
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sampling of the training set results in greater tree diversity, which trades higher bias for
lower variance for an improved overall model.
The Extra-Trees algorithm furthers the randomization of Random Forests by also
using random thresholds for each feature when growing each random Decision Tree,
rather than searching for the best possible thresholds as in regular Decision Trees and
Random Forests. This explicit randomization of the cut-points and features combined
with ensemble averaging have been shown to reduce variance compared to other
weaker randomization schemes found in other algorithms like Random Forests.148 A
useful property of Extra-Trees is that the relative importance of each feature can be
measured incidentally. Relative feature importance is computed by averaging the
amount each feature contributes to reducing the prediction error over all trees in the
forest.
Relative feature importance was calculated in this study by averaging the results
from 50 different Extra-Trees, where each Extra-Tree forest consisted of 500 trees.
Standard values were used for other parameters within the Extra-Trees regression
estimator provided by scikit-learn, which is the open-source machine learning software
package utilized for feature selection and model development in this study unless
otherwise specified.149
Univariate statistical methods using mutual information and linear regression
were used to quantify relative feature importance to compare with the Extra-Trees
method. Mutual information is a statistic for measuring the dependency between
variables. In contrast to linear regression, which only quantify linear relationships
between data sets, mutual information can detect either linear or nonlinear
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relationships. Specifically, mutual information is defined as the reduction in uncertainty,
or entropy, of one random variable due to the knowledge of another random variable.150
Given two continuous variables A and B with a joint probability density function +(C, D)
and marginal probability density functions +(C) and +(D), the mutual information E(A; B)
is the relative entropy between the joint distribution and the product distribution
+(C)+(D), or

E(A; B) =

G +(C, D) log K
'∈) +∈,

+(C, D)
L -C-D
+(C)+(D)

Mutual information values were computed for each feature to measure their
dependence relative to the target values.
Linear regression was used to quantify the linear relationship between the
feature and target variable space. First, the correlation between each feature set A and
the target set B was computed as
(A − @) )(B − @, )
!) !,
where @ and ! represent the mean and standard deviation respectively. The strengths
of the linear correlation between each feature and the set of target values were
computed and used to measure the relative feature importance in this study.
After relative feature importance was assessed with these three different
selection methods, different numbers of features were selected for each set of relative
importance rankings. Specifically, subsets of the 5, 10, 25, 50, 100, 175, and 241 (i.e.
all features) most important features according to each of the three feature importance
methods were selected for training a given machine learning model, resulting in 21
models (three feature selection methods times seven dataset subsets of varying size)
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for each class of machine learning algorithm. The impact of the number of selected
features and type of feature selection method on model performance was then
assessed.
3.2.3.

Training Machine Learning Regression Algorithms
This study surveyed and evaluated the performance of four different categories

of machine learning algorithms for this regression problem. Below are brief descriptions
of each specific algorithm along with the model-specific, tuned hyperparameters
determined via cross-validated searches. The interested reader can find more details in
the supplementary material regarding the hyperparameter tuning methods used for
each model. The tuned hyperparameters of the models discussed in ensuing results are
also summarized in the supplementary material for convenience (Table C.2). For each
of the 21 combinations of number of features selected and feature selection methods
detailed in Chapter 3.2.2, the best predictor was selected from these cross-validated
searches and were then refit to the entire training set. This optimized fit was evaluated
on the testing set and was used to compare the performance of different learning
algorithms and to assess the impact of number of features selected and type of feature
selection method on model performance.
3.2.3.1.

Linear Regression Models

One of the simplest machine learning models is linear regression. A linear model
makes a prediction by computing a weighted sum of the input features, plus a constant
bias term. This equation for linear regression model prediction can be expressed as
DN = ℎ- (P) = Q # ∙ P
where DN is the predicted value, θ is the model’s parameter vector containing the bias
term θ. and the feature weights θ/ to Q0 , P is the instance’s feature vector (containing C.
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to C0 , with C. always equal to 1), and ℎ- is the hypothesis (i.e. prediction) function, using
the model parameters Q. Training a linear regression model means finding the set of
parameters such that the model best fits the training set. This can be done by finding
the parameter vector Q that minimizes the MSE, defined as
5

1
4
MSE(X, ℎ- ) = Z ] ^_ℎ- _P(2)` − a(2) `
\
67/

where \ is the number of instances in the dataset, P(2) is a vector of all the feature
values of the ith instance in the dataset with a(2) being its associated target value (the
desired output value for that instance), X is a matrix containing all the feature values of
all instances in the dataset, and ℎ- is the system’s prediction or hypothesis function
parametrized by Q.
A strategy to reduce the likelihood of overfitting in linear regression and other
machine learning models is to regularize, or constrain, the weights. In addition to
unregularized linear regression, three types of regularized linear models were explored
in this study: Ridge Regression, Lasso Regression, and Elastic Net. Ridge Regression
8

adds an ℓ& -norm regularization term to the cost function, equal to & ∑067/ Q6& , where d is a
hyperparameter to control the amount of regularization.151 Similarly, Lasso Regression
instead adds an ℓ/ -norm regularization term to the cost function, equal to d ∑067/|Q6 |.152
Both algorithms include the hyperparameter d to control the amount of regularization.
Elastic Net utilizes both regularization terms found in Ridge Regression and Lasso
regression and allows control of each type of regularization through a mixing parameter
&; Elastic Net is equivalent to Ridge Regression when & = 0 and equivalent to Lasso
Regression when & = 1. Therefore, since the hyperparameter optimization of the Elastic
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Net model included both Lasso and Ridge Regression models, only Elastic Net results
are shown here for simplicity. The Elastic Net hyperparameters d and & were tuned to
0.594 and 1, respectively, via a 10-fold cross-validated grid search.
3.2.3.2.

Support Vector Machine

SVMs are powerful and versatile models capable of performing linear or
nonlinear classification and regression. SVMs implement kernels to map input features
to higher dimensional spaces to facilitate nonlinear predictive modeling. The SVM
regression algorithm originally proposed by Drucker et al. depends on only a subset of
the training set such that if the predicted value is within a certain tolerance f, the loss is
zero, while if the predicted point is outside this f-tube, the loss is the magnitude of the
difference between the predicted value and the radius f of the tube.153 Therefore, SVMs
are f-insensitive, where adding training instances within the f margin does not affect
model predictions.
The linear, polynomial, Gaussian Radial Basis Function (RBF), and sigmoid
kernels were tested in this study. Each are defined as
Linear:
Polynomial:
Gaussian RBF:
Sigmoid:

g(h, i) = h# ∙ i
g(h, i) = (;h9 ∙ i + &):
g(h, i) = exp (−;‖h − i‖& )
g(h, i) = tanh(;h9 ∙ i + &)

where ; and & are kernel hyperparameters. Tuned hyperparameters for SVMs were
optimized via a 5-fold cross-validated randomized search with 250 iterations (Table 3.2).
Table 3.2. Selected hyperparameter values for the SVM model.
SVM Parameter
Selected Value
Kernel
Gaussian RBF
C
6.407
f
0.094
(table cont’d)
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SVM Parameter
Selected Value
;
1
(for Polynomial,
Gaussian RBF,
q;$<=>%$? × ! &
and Sigmoid kernels)
Note: ! ! is the variance of the given feature distribution

3.2.3.3.

Tree-Based Regression

3.2.3.3.1

Decision Trees

As mentioned previously in Chapter 3.2.2, Decision Trees are flexible algorithms
capable of classification or regression tasks and can even predict multiple outputs.
While they can fit complex datasets, Decision Trees are nonparametric models that
have a strong tendency to overfit the training data if left unconstrained or not regularized
appropriately. Regularization parameters for the tuned Decision Tree model in this study
were determined to be a maximum tree depth of 3, a minimum number of samples
required at each node of 17, with the mean absolute error (MAE) loss function used to
measure the quality of a split. Standard values were used for remaining model
parameters during training. The Classification and Regression Tree (CART) algorithm
introduced by Breiman et al. was used to train the decision tree models in this work.154
3.2.3.3.2

Random Forests

Random Forests are a class of machine learning algorithm consisting of an
ensemble of Decision Trees which are grown by searching for the best feature among a
random subset of the feature space, instead of searching for the best among all
features as in normal Decision Trees. As indicated in Chapter 3.2.2, this increases bias
and decreases variance to generally yield a better model overall. The same treegrowing hyperparameters and their associated ranges of values given in Chapter
3.2.3.3.1 were similarly optimized for Random Forests. The optimized Random Forest
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model had a maximum tree depth of 12, a minimum number of samples required at
each node of 4, and an MSE loss function. Additionally, the number of trees in the
optimized forest was determined to be 124.
3.2.3.3.3

AdaBoost

Boosting algorithms are those incorporating and combining an ensemble of weak
models into a stronger composite model. This process is generally sequential, where
subsequent models are trained based on the errors of the preceding model. AdaBoost
is a popular boosting learning algorithm that begins by fitting a base regressor to the
training data and then iteratively fits copies of the regressor on the same dataset while
adjusting the relative weights of training instances associated with the largest errors.155
A standard Decision Tree with a maximum depth of 5 levels was the base
regression model used for optimizing and training the AdaBoost models in this study.
The optimized AdaBoost-specific hyperparameters of describing the maximum number
of estimators at which boosting was terminated and learning rate, which scales the
contribution of each regressor, were determined to be 91 and 1.311 respectively.
3.2.3.3.4

Gradient Boosting

Gradient Boosting is another popular boosting algorithm that differs from
AdaBoost, which adjust instance weights at every iteration, by fitting new predictors to
the residual errors made by the previous predictor.156 This allows for optimization of
arbitrary differentiable loss functions, where each predictor is fit on the negative gradient
of the given loss function at each iteration.
Like with the AdaBoost models, Decision Trees were used as the base
regression model for training and optimizing Gradient Boosting models. The determined
hyperparameter values for the optimized Gradient Boosting model were a maximum
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number of estimators of 616, a learning rate of 0.007, a fraction of training samples to
be used for fitting the individual base predictors of 0.444, a maximum tree depth of 14,
and a minimum number of samples required to split an internal node of 6.
3.2.3.4.

Artificial Neural Network

Artificial Neural Networks (ANNs) are popular machine learning algorithms that
take inspiration from the biological architecture found in the brain. ANNs are commonly
used models due to their robustness and scalability, which makes them useful for large
and complex tasks like mastering the game of Go.157
Hyperparameter tuning in neural networks is a challenging problem given the
potentially large parameter space. Although the number of tunable parameters gives
ANNs their flexibility, the topology of even a simple network can be altered by
parameters such as the number of hidden layers, the number of neurons per layer, the
type of activation function used in each layer, among others.
Neural networks in this study were developed using Keras.158 The set of
hyperparameters yielding the best validation MAE (20% of training set) was chosen as
optimal and were used for final training and testing. Table 3.3 lists the optimized
hyperparameter values for the ANN model.
Table 3.3. Selected hyperparameters for the ANN model.
Tuned
Parameters
Learning Rate
0.280
Number of neurons in first layer 27
Batch Size
94
Number of hidden layers
3
Topology Shape†
‘funnel’
Epochs
275
Dropout
0
Talos-specific hyperparameter

(table cont’d)
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Tuned
Parameters
Optimizer
Nadam
Losses
MAE
Hidden layers activation function Linear
Output layer activation function relu
Talos-specific hyperparameter

†

Topology shapes are package-specific names where ‘brick’ assigns the same number of
neurons in each layer, ‘triangle’ decreases the number of neurons by a constant number with
each layer so that the shape resembles a triangle, and ‘funnel’ decreases the number of
neurons by floor of the difference between the specified number of neurons in the first layer
and last layer divided by the number of desired hidden layers, resulting in a funnel shape.

3.2.4.

Overall Model Comparison
Once optimal hyperparameters were selected via cross-validated searches as

described in Chapter 3.2.3, models for each type of algorithm, feature selection method,
and number of selected features were evaluated on the separate testing set that was
unseen during training. Models with the best MAE within each class of learning
algorithm were used to compare overall performance. It is important to note MAE is
reported as a percentage in this work because the variable being evaluated (GPR) is
expressed as a percentage. Specifically, MAE is defined in this study as:
∑067/|DN6 − D6 |
stu =
q
where DN6 is the predicted GPR and D6 is the true GPR. Since GPRs are the percentages
of points passing the given gamma criteria, the individual absolute errors |DN6 − D6 | and
therefore the MAE of predicted GPRs are expressed as percentages. Further, values of
MAE in this work should not be confused with mean absolute percentage errors.
Top performing models were selected to further assess the impact of suspected
outliers among the labeled data (i.e. GPRs), which was performed by iteratively
removing samples with GPRs outside 1.5 times the interquartile range (25%-75%
distribution quartiles). Performance for these top performing models was also
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statistically compared using Wilcoxon signed-rank tests (with significance level set at p
= 0.05) to “random guessing” by fitting the training and testing datasets to Gaussian
distributions and then randomly sampling those distributions to obtain ‘random’
predictions.
3.3.
3.3.1.

RESULTS
Feature Analysis
Relative feature importance was measured using three feature selection

methods: forests of Extra-Trees, mutual information, and linear regression. Table 3.4
shows the relative importance of each feature category – according to the sum of
feature importances of each individual feature within each category – for each of these
three selection methods. The SAS feature category was most important for each
selection method. Generally, feature groups related to aperture size and shape or MLC
leaf gaps (e.g. FAOC, LG, etc.) were also important for accurately predicting GPRs.
Regarding the raw features within each feature category, the five most important
features using forests of Extra-Trees were (in order of decreasing importance) the lung
treatment site, the prostatic fossa treatment site, the mean weighted LG, the mean
collimator angle, and maximum SAS at 40 mm. The five most important features with
the mutual information feature selection method were the mean weighted FAOC at 25
mm, the SAS at 75 mm, the mean weighted LG, the SAS at 80 mm, and the SAS at 45
mm. Lastly, the five most important features using the linear regression method were
the SAS at 50 mm, the SAS at 45 mm, the SAS at 55 mm, the maximum SAS at 45
mm, and the SAS at 60 mm. It is interesting to note the differences in feature
importance among the three selection methods. The two most important features using
forests of Extra-Trees were lung and prostatic fossa, both of which are treatment sites.
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Whereas for the mutual information and univariate linear regression methods, the top
features were related to aperture shape and the size of the gaps between opposing
MLC leaves. Features were weakly correlated with GPRs, with SAS 50 mm having the
Pearson correlation coefficient with the largest magnitude of 0.38 (p < 0.001; Figure
3.2). Overall, 113 out of the 241 raw features having significant p-values of less than
0.05 and 32 features had correlation coefficient magnitudes of at least 0.3.
Table 3.4. Rankings of relative importance of feature categories according to the sum of
all raw features within each classification for each feature analysis method.
Summed
Feature
Extra-Trees
Mutual Information Linear Regression
Rank
1
SAS
SAS
SAS
2
FAOC
FAOC
LG
3
Site
PI
FAOC
4
LT
LG
AA
5
AP
LM
Site
6
LM
LT
JT
7
PI
AA
EM
8
LG
AP
FFF
9
JM
Site
Dose Rate
10
Machine
JP
MU Factor
11
AA
JM
AP
12
JT
JT
JM
13
Collimator Angle
MU Factor
PI
14
JP
EM
LM
15
Arc Length
Machine
Machine
16
MU Factor
CAS
LT
17
FFF
FFF
JP
18
Dose Rate
Dose Rate
Collimator Angle
19
CAS
Collimator Angle
Arc Length
20
MCS
MCS
Number of Arcs
21
EM
PM
MCS
22
PM
Arc Length
CAS
23
Number of Arcs
Number of Arcs
PM
Figure 3.3 shows the distribution of dataset GPRs as a function of treatment site.
Lung had the highest mean GPR overall of 91.05% with a standard deviation of 6.67%,
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while prostatic fossa had the lowest mean GPR of 83.35% with a standard deviation of
6.29%. Additionally, lung had the most samples with GPRs less than or equal to 80% (n
= 10) while prostatic fossa had the highest proportion of samples that had GPRs less
than or equal to 80% (30%).

Figure 3.2. Scatter plot of GPR vs. SAS – 50 mm over the dataset along with the
Pearson correlation coefficient (R). Note the feature axis has been standardized.
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Figure 3.3. Distribution breakdown of dataset with respect to treatment site. Here, the
grey circles indicate the distribution mean and crosshairs indicate values lying outside
1.5 times the interquartile (25%-75%) range.
3.3.2.

Optimized Model Performance
After relative feature importance was quantified using the three selection

methods, different machine learning algorithms were trained using subsets of varying
numbered selected features as determined by each method. Hyperparameters were
optimized for each learning algorithm and feature set pair using a cross-validation
searching method as described in Chapter 3.2.3. Each model was trained and
subsequently evaluated on the testing set, after which the models within each class of
algorithm with the lowest test MAE was selected for comparison (Table 3.5). Optimized
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hyperparameters for each model listed in Table 3.5 can be found in the supplemental
material.
Table 3.5. Testing error for best performing model within each class of learning
algorithm with associated feature selection method and number of features. Mean and
standard deviations of testing error from cross-validation is also included. Note that all
models underwent 10-fold cross-validation, except for SVM, for which 5 folds were
used.
Feature Number
Cross-Validation
Test
Algorithm
Selection
Of
MAE (@ ± !; %) MAE (%)
Method Features
Linear Regression
4.20 ± 0.57
4.29
ET
5
Elastic Net
4.34 ± 0.69
4.17
LR
50
SVM
3.96 ± 0.42
3.85
LR
100
Decision Tree
4.37 ± 0.72
4.14
LR
10
Random Forest
3.91 ± 0.60
3.98
ET
100
AdaBoost
3.99 ± 0.51
3.98
ET
50
Gradient Boosting
4.06 ± 0.52
3.94
ET
50
ANN
4.24 ± 0.69
4.01
ET
50
Abbreviations: LR = Linear Regression; ET = Extra-Trees

Mean cross-validation MAE was consistent with test MAE for each learning
algorithm, indicating the models generalized as expected from training to testing. The
best (i.e. lowest) MAE on the testing set was the SVM model (3.85%) followed by the
Gradient Boosting model (3.94%). Random Forest and AdaBoost models also achieved
test MAEs of less than 4%. In addition, the optimal number of features for each model
seemed to be between 50 and 100 of the most important features according to ranking
with Extra-Trees and linear regression feature selection methods.
3.3.3.

Top-Performing Models
The top two performing models, SVM and Gradient Boosting, were selected for

further inspection and analysis. Figure 3.4 shows the behavior of cross-validation error
as a function of feature selection method and number of features selected for each
model. Generally, the cross-validation error decreased as the number of selected
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features increased for both models but plateaued after 100 selected features. SVM
models using the Extra-Trees and linear regression feature selection methods resulted
in lower cross-validation error than the mutual information method when using higher
numbers of features. Also, cross-validation error for both models using the Extra-Trees
feature selection varied less with the number of selected features compared to mutual
information and linear regression selection methods.

Figure 3.4. Cross-validation MAE of SVM (a) and Gradient Boosting (b) models as a
function of feature selection method and number of selected features. The mean crossvalidation error and standard deviation is plotted. Note that 5 folds were used for SVM
models and 10 folds were used for Gradient Boosting models.
The impact of the number of training samples on training and cross-validation
error was also assessed for these models. Figure 3.5 shows these learning curves
(which plot training and cross-validation error against number of training samples) for
the optimized models. The SVM learning curve shows the validation error gradually
decreasing with increasing training samples, while the training error stabilizes after
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about 75 training samples. The Gradient Boosting learning curve shows training and
validation error to also be decreasing with the size of the training set. However, the
difference in the training and validation errors for the Gradient Boosting model highlight
the tendency of Decision Trees to overfit the training data compared to the SVM model.

Figure 3.5. Learning curves, which plot error as a function of the number of training
samples, for the optimized SVM (a) and Gradient Boosting (b) models. Note that 10-fold
cross-validation was used for both models to construct these curves. Average values
resulting from cross-validation are shown via markers, with the associated standard
deviation given via the shaded regions.
Composite testing error results from 5-fold cross-validation over the entire
dataset for the SVM and Gradient Boosting models are shown in Figure 3.6 and Figure
3.7 respectively. The SVM model resulted in 3.75 ± 0.29% (mean ± standard deviation)
testing MAE while the Gradient Boosting model resulted in 3.81 ± 0.22% MAE. This
represents a significant 41.1% (p < 0.001) and 40.6% (p = 0.02) average improvement
respectively over “random guessing,” which had an MAE of 6.41 ± 4.98%. The SVM
model predicted 51.2% and 74.4% of the testing samples to within 3% and 5% error,
respectively. Whereas the Gradient Boosting model predicted 47.2% and 71.2% of the
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Figure 3.6. 5-fold cross-validation testing performance for the optimized SVM model. (a)
and (c) plot the true GPR values against the predicted GPR values from the model
when trained and tested with the full dataset and when trained and tested with
suspected outliers removed from the dataset, respectively. (b) and (d) are associated
histograms of the differences between the true and predicted values.
testing samples to within 3% and 5% error, respectively. The maximum errors were
23.7% and 17.8% for the SVM and Gradient Boosting models respectively. When
suspected outliers were removed from the dataset, the average testing MAE improved
by 0.41% and 0.47% for the SVM and Gradient Boosting models respectively. Most
noticeably, the percentages of instances with errors less than 10% were improved from
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94.2% to 96.64% and from 95.8% to 98.32% for the SVM and Gradient Boosting model
respectively when removing these suspected outliers.

Figure 3.7. 5-fold cross-validation testing performance for the optimized Gradient
Boosting model. (a) and (c) plot the true GPR values against the predicted GPR values
from the model when trained and tested with the full dataset and when trained and
tested with suspected outliers removed from the dataset, respectively. (b) and (d) are
associated histograms of the differences between the true and predicted values.
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3.4.

DISCUSSION
This study collected a large retrospective dataset of VMAT plan and QA data in

order to investigate the feasibility of developing machine learning models for predicting
GPRs from an array of treatment plan parameters and complexity metrics. The selected
features were found to be weakly correlated with the target variable, which resulted in
the best-performing machine learning model (SVM) yielding an average cross-validated
test MAE of 3.75%. These results may reveal potential limitations within the present
dataset when compared to model performance in existing literature such as in Valdes et
al., which reported being able to predict GPRs for fixed-gantry IMRT plans to within
3%.95 However, each machine learning model investigated in this study achieved
improved testing MAE compared to “random guessing” and was able to capture the
overall relationship between the independent and dependent variables present in the
available dataset.
Several previous studies have showed promising results for predicting GPRs for
“fixed-gantry” IMRT plans using machine learning and deep learning.95-99 Fewer studies
have been published concerning VMAT QA. Granville et al. recently applied an SVM
model for classifying results of VMAT QA measurements performed with biplanar diode
arrays into ‘hot’, ‘cold’, or ‘normal’ median dose difference categories.122 Ono et al. used
regression tree analysis, multiple regression analysis, and ANNs to predict GPR
measurements using a helical diode array based on plan complexity metrics.101 Novel
aspects of this study compared to these previous works are the comprehensive
comparison of different standard machine learning models, the investigation of feature
importance using three different selection methods, and the assessment of the
relationship between both the number of features and the type of selection method used
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during training and the resulting model performance. The SVM model was found to be
the best-performing model and the machine learning algorithms generally performed
better with fewer number of features selected with either forests of Extra-Trees or linear
regression. Additional strengths of this study are the collection of a large dataset along
with inspecting a large array of plan complexity metrics and features. Although the
features were found to be weakly correlated with the target variable overall, more than
100 features were significantly (p < 0.05) correlated. The feature selection methods
used were able to improve model performance compared to models trained with all
available features as shown in Table 3.5, which indicates reducing the number of
selected features provided the best performance across all models, in addition to
reducing model dimensionality. Also, the specific combination of technologies (Pinnacle
TPS, Elekta LINACs, and MapCHECK2 diode-array) used in this study is unique relative
to previous studies using machine learning to predict GPR measurements to our
knowledge.
An interesting result from analyzing the relative feature importance in accurately
predicting GPRs was that the lung and prostatic fossa treatment sites were the two
most important features according to the forests of Extra-Trees selection method. Unlike
previous studies, which have not included treatment site as an input feature, this result
could indicate the need for site-specific models. This is similar to the results Valdes et
al. observed, where one treatment machine was found to have different profile
characteristics affecting model performance that suggested machine-specific models
may lead to more robust predictions. Further research and a larger number of samples
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within each treatment site are warranted in the future to evaluate differences in sitespecific models.
The present work shares similarities with previous studies such as the number of
samples and the plan complexity metrics and parameters included in the feature space.
The features selected for this study (which were taken or adapted from the literature
listed in Table 3.1) showed weaker correlations with the target GPR values than the
correlations found in previous studies for those same features.112,113,120 However,
features based on the aperture size (e.g. SAS) were found to have the strongest linear
correlation with GPRs (Figure 3.2), which is consistent with Crowe et al.144 The weaker
correlations found in this study could be a result of differences in the underlying data in
each work, such as the institution-specific combination of technologies and clinical
protocols utilized for treatment planning QA.
The differences in testing errors between this study and previous results may be
due to the spread in the distribution of GPRs in the present dataset. The majority of
GPR distributions in these previously mentioned studies were heavily concentrated
towards the 100% GPR boundary, which potentially clouds the true relationship
between features and dose differences. In contrast, the target distribution used in this
study had an average value of 89.39% and a standard deviation of 6.01%. The percent
dose-difference/distance-to-agreement gamma index criteria of 3% and 3 mm with local
normalization was selected for this study to enable comparison with previous studies
and to obtain a target distribution with meaningful information about the underlying
differences between planned and measured dose distributions. It is also important to
note each sample used in the study passed the clinical QA protocol at our institution.

64

The GPRs reported here were computed without incorporating measurement
uncertainty (which is typically turned on for clinical evaluation) associated with the
device due to factors such as, temperature change, accelerator output fluctuation, array
calibration accuracy, and electronic measurement precision.
Training time was not considered for the purposes of this study but is still
important to contemplate prior to clinical implementation. Training times qualitatively
varied depending on the type of machine learning algorithm, number of features used,
and the number of iterations executed for hyperparameter optimization searches.
However, for each of the machine learning models in this study, once the model has
been trained and has had its hyperparameters tuned, real-time predictions can be
given. Therefore, predictions can be quickly provided during a clinical scenario given the
necessary input features for the model.
It is possible the correlation between plan complexity and GRPs in this study was
also limited by the 1 cm minimum leaf gap constraint used at our institution. Additionally,
all but four samples in the dataset utilized four degrees for control point spacing during
VMAT plan optimization. Using a finer gantry spacing resolution could result in more
accurate dose computation, although four degrees has been shown to provide an
optimal balance between plan quality and complexity.113,135 Further, the specific
combination of technologies and clinical techniques – such as the radiation-delivery
machine, the TPS software and optimization settings used to design the clinical
radiation treatment plans, the measurement device and analysis technique used for
performing QA, etc. – used in this study could also have led to a dataset with weaker
relationships between plan features and delivery errors. For example, the 1 cm
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minimum leaf gap constraint likely restricted the possible range of complexity for the
plans in this study’s dataset, which could have led to weaker correlations with QA
outcomes when compared to studies with plans with a looser leaf gap constraint.
Differences in these types of underlying factors that characterize the feature-target
relationship possibly prevented the machine learning algorithms surveyed in this work to
achieve error rates as low as previously reported in IMRT and VMAT QA studies.
However, each machine learning model was able to achieve a minimum of 37%
improvement over “random guessing,” with the top-performing SVM model improving by
41.1%. Therefore, it is important to note that results from the present and previous
studies are specific to the particular dataset used, which warrants future research
investigating how the relationship between complexity features and QA outcomes
behaves as a function of varying delivery, planning, and QA parameters.
Previous investigators have noted the numerous clinical benefits of models for
predicting VMAT QA measurements. Most notably, a machine learning model could
identify a treatment plan that is predicted to present unacceptable dose delivery errors
before measurement, allowing the plan to be modified beforehand to save time.
Alternatively, a machine learning model for predicting GPRs for VMAT plans could be
inserted into the planning stage to provide QA-based information to the optimizer and
planner in real-time. Predicted GPR output from a machine learning model could be
added to the optimization cost function to penalize search solutions that reduce the
predicted GPR, which would result in a plan guided by both plan quality (e.g. dosebased) and delivery accuracy (e.g. QA-based) endpoints. Our group is currently
pursuing this avenue of research. Previous works have also investigated the feasibility
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of developing convolutional neural networks to predict GPRs based on fluence maps for
fixed-gantry IMRT and were able to achieve comparable performance to machine
learning models based on complexity metrics.97 While the purpose of this work was
specifically to perform a systematic evaluation of different machine learning models for
predicting VMAT QA outcomes based on complexity features, a logical next progression
would be to develop a convolutional neural network for predicting VMAT QA outcomes
to mirror the progression of previous literature on predictive models for fixed-gantry
IMRT QA.
3.5.

CONCLUSION
Models predicting VMAT QA outcomes can help improve clinical efficiency by

highlighting treatment plans likely to fail QA prior to measurement. This work is among
the first to investigate and compare several machine learning algorithms for predicting
VMAT QA measurements using the specific planning and measurement technologies at
our institution. Model features were based on treatment plan complexity metrics and
parameters and their relative importance in accurately predicting GPRs was assessed
via forests of Extra-Trees, mutual information, and linear regression. Features were
found to be weakly correlated with GPRs, resulting in a test MAE of 3.75% for the best
performing model (SVM). While previous studies have shown the ability of machine
learning models to predict QA outcomes with a high degree of accuracy, the results of
this study show model performance may be limited by characteristics of the underlying
data, particularly the unique and specific combination of technologies and clinical
parameters used to generate treatment plans and perform quality assurance. Further,
machine learning models were developed and shown to be significantly better than
“random guessing,” but the results from this study indicate feature analysis and
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selection should be performed when establishing a machine learning model for
predicting QA measurements.
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4. USE OF MACHINE LEARNING ALGORITHM DURING
OPTIMIZATION TO IMPROVE PATIENT-SPECIFIC QUALITY
ASSURANCE IN VOLUMETRIC MODULATED ARC THERAPY
PLANS
4.1.

PURPOSE
The purpose of this study was to evaluate the feasibility of a QA-based planning

tool, whereby QA outcomes for VMAT treatment plans are directly optimized using
machine learning without substantially degrading the dosimetric quality of the original
plan.
4.2.
4.2.1.

MATERIALS AND METHODS
Description of Algorithm
An in-house algorithm was developed to optimize predicted QA endpoints by

modifying existing mechanical parameters determined from Chapter 3 to be important
for predicting the deliverability of a radiotherapy treatment plan. This was accomplished
through utilization of the machine learning algorithm described in Chapter 3 to predict
the QA outcomes based on complexity features of VMAT treatment plans.
The proposed algorithm – existing independently from a commercial TPS – takes
an existing VMAT treatment plan file as input with an initial predicted GPR, and returns
a modified version of the original VMAT treatment plan with mechanical parameters
adjusted to result in an increased predicted GPR (see Figure 4.1). Before this QA
optimization, the initial predicted GPR is computed for the original plan file by the
previously mentioned machine learning model. This initial prediction serves as a
reference point for the performance of subsequent plan modifications relative to
changes in predicted QA outcome. After this initial QA outcome prediction, the algorithm
selects specific features of the plan that the machine learning model deems to be the
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most important or influential to plan deliverability. These selected plan features are then
modified, using logic informed by the feature analysis results detailed in Chapter 3.3.1,
before the machine learning model assesses the new predicted QA outcome as a result
of the modifications to the mechanical parameters. This process is iterated over a given
number of optimization iterations, after which the algorithm returns the plan file with the
best predicted QA outcome.

SVM
Model

GPRs

Plan Complexity

Initial
Plan

Predicted GPR:
89%

QA-optimized
Plan
Novel machine
learning-based
optimization

New Predicted GPR:
91%

Figure 4.1. Conceptual overview of the proposed QA-based treatment planning
optimization technique. First, an inversely optimized plan is taken as input with an initial
predicted GPR. Then mechanical features identified by our machine learning model are
randomly displaced in order to produce a new GPR prediction. This process is iterated
to produce the largest positive GPR change.
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More specifically, the algorithm was designed using the Python programming
language. Given an initial DICOM RT-Plan file of a VMAT treatment plan, the algorithm
begins by extracting the necessary complexity features (see Chapter 3.2.1.1 and Table
3.1) as required by the machine learning algorithm to predict the QA outcome of the
original plan. The machine learning model implemented in Chapter 3 was a support
vector machine (SVM), developed on a training and testing set of 400 and 100 previous
VMAT treatment plans, respectively. The SVM model was designed to use an array of
plan complexity features to predict GPRs of a given VMAT plan using 3%/3mm percent
dose-difference and distance-to-agreement gamma criteria with local normalization. The
100 most important complexity features were selected using linear regression tests out
of a total of 241 raw plan features, belonging to 23 general plan parameter categories
(Table 3.1). As mentioned in Chapter 3.3.1, the feature category selected as the most
important feature group for accurately predicting GPRs was the small aperture score, or
SAS, for all three selection methods. Further, the five most important features selected
according to the linear regression method were all based on the SAS, defined as the
fraction of open MLC leaf gaps less than a given distance. As a result, although features
were found to be weakly correlated with GPRs, the SAS feature at 50 mm had the
strongest correlation with GPR (Figure 3.2). The model hyperparameters – including the
kernel function, associated kernel hyperparameters, and f – were tuned via a 5-fold
cross-validated randomized search over 250 iterations (Table 3.2). This SVM model,
which was the best performing model out of those surveyed in Chapter 3, achieved a 5fold cross-validated testing mean absolute accuracy of 3.75 ± 0.29% (mean ± standard
deviation).
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After the GPR of the initial VMAT plan was predicted using the SVM model, the
algorithm selected every open LG less than 50 mm over all control points in every beam
within the plan file, as these features were previously determined to be most important
for predicting GPRs. Then, each LG was widened by a random amount sampled from a
uniform distribution between 0 and a maximum distance specified by the user.
Randomized MLC leaf displacements were selected for investigation because their
impact on the resulting calculated dose distribution is smaller compared to systematic
leaf displacements.159 In order to avoid having the resulting changes in MLC leaf
positions violate the minimum MU per leaf travel distance machine constraint, the
algorithm also increased the segment weight so that the minimum MU per leaf travel
distance never fell below 0.25 MU/cm. The modified MLC leaf positions and segment
MUs were then saved, with which new complexity features were computed and input to
the SVM model for evaluating the modified plan’s new predicted GPR. The modified
MLC positions, segment MUs, and predicted GPRs were recorded after each
optimization round. This process would be repeated for a given number of iterations set
by the user, after which the algorithm would return a DICOM RT-Plan file with the MLC
positions and segment MUs that yielded the highest predicted GPR. Since this QAbased optimization occurred external to a commercial TPS, changes in the resulting
dose distribution of these QA-optimized plans were unable to be assessed until reimporting the plan and computing the dose. As mentioned previously however, small
random MLC leaf displacements were utilized specifically to minimize meaningful
changes to the subsequent dose distribution.
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4.2.2.

Feasibility Assessment
The feasibility of this in-house, QA-based optimization algorithm was evaluated

on a set of 13 treatment plans of previously treated prostate patients. Each plan was
designed with two co-planar 6 MV VMAT arcs with the guidance from a previously
established in-house KBP system.103,125,160 This KBP implementation predicts the lowest
achievable bladder and rectum dose-volumes for new patients among anatomically
similar previous patients available in a database, which has been shown to lead to
significant reductions in the mean dose to the bladder and rectum compared to
reference clinical plans while maintaining clinically acceptable dose to the target.103,125
However, significant increases in complexity and diminished QA outcomes were also
observed for these plans.160 Therefore, plans designed with this KBP method were
selected for this study to assess the extent to which their predicted deliverability could
be improved via this algorithm without compromising their dosimetric quality.
The DICOM RT-Plan file for each of the 13 KBP plans were exported from a
commercially available TPS. Each plan was modified with the previously described QAbased optimization algorithm (see Chapter 4.2.1) with varying maximum LG
displacement and number of iteration settings. Specifically, maximum LG displacements
of 1, 3, and 5 mm were used with both 25 and 1000 optimization iterations. This
resulted in a total of 6 QA-optimized DICOM RT-Plan files for each patient. In order to
assess the dosimetric changes resulting from these mechanical parameter
modifications, each DICOM file was then imported back into the same TPS in which the
original KBP plan was designed. Then, the same dose grid settings (i.e. 4 mm/voxel
resolution and grid coordinates) from the original KBP plan were applied to each QA-
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optimized plan before the dose was recomputed. Dose distributions of all plans for each
patient were scaled so that 95% of the PTV received the full prescribed dose.
Differences in predicted GPRs, plan complexity metrics, dose, and
radiobiological metrics were assessed as a function of maximum LG displacement and
number of optimization iterations. The specific plan complexity metrics that were
investigated in this study were: MU factor, defined as the total planned monitor units
normalized by the fractional prescription dose; modulation complexity score (MCS), a
metric introduced by McNiven et al. for fixed-gantry IMRT and later adapted for VMAT
by Masi et al. quantifies aperture area variability and leaf sequence variability into a
composite value;113,120 edge metric (EM), a parameter introduced by Younge et al. that
measures the “edge” in a plan through the ratio of MLC leaf side lengths over aperture
areas;112 mean leaf motion (LM), defined as the average distance an MLC leaf travels
per degree of gantry rotation in mm/deg; mean LG in mm; mean aperture area in mm2;
and the small aperture score at 50 mm.
The radiobiological metrics used in this study were equivalent uniform dose
(EUD), tumor control probability (TCP) and normal tissue complication probability
(NTCP).161 EUD has been described by Wu et al. as the biologically equivalent dose
from a uniform distribution that would result in the same cell kill in the volume as the
given non-uniform dose distribution.162 Differing from this linear-quadratic cell survival
model, Niemierko introduced a phenomenological model of EUD defined as
/
<
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that can be used for both tumors and normal tissues, where { is a unitless model
parameter that is specific to the normal structure or tumor of interest, and x6 is unitless
and represents the |‘th partial volume receiving the biologically equivalent physical dose
of 2 Gy, uy:&! .161,163 Specifically, uy:&! is defined as

uy:&! = :6 ×

where q; and -; =

}d•~ +

:6•
q; Ä
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:6
•q; are the number of fractions and dose per fraction size of the

treatment course that the |‘th partial volume receives, respectively. d•~ is the tissuespecific linear-quadratic parameter of the organ being exposed.164 A parametrization of
the dose-response characteristics of tissues was proposed to calculate EUD-based
TCP and NTCP, where TCP is calculated according to
/ÇÉ =

1
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The /Ç:@. is the tumor dose needed to control 50% of the tumor assuming a
homogenous irradiation, and ;@. is a unitless model parameter that is specific to the
normal structure or tumor of interest and characterizes the dose-response curve.
Similarly, NTCP is computed according to
Ñ/ÇÉ =

1
/:@. AB"#
1 + }uv:
Ä

where /:@. is the tolerance dose for a 50% complication rate at a specific time interval
(typically taken to be 5 years in normal tissue tolerance studies) when the whole organ
is irradiated homogenously.
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TCP for the prostate and NTCPs for the bladder, rectum, and femoral heads
were computed for all plans for each patient. Model parameters used in this study were
taken from previous literature and are given in Table 4.1.164
Table 4.1. Tissue-specific model parameters used to compute EUD-based TCP and
NTCP.164
d
Tissue
{
;@. /Ç:@. (Gy) /:@. (Gy) •~ (Gy)
Prostate -10
1
28.34
NA
1.2
Bladder
2
4
NA
80
8.0
Rectum
8.33 4
NA
80
3.9
Femur
4
4
NA
65
0.85
Differences in these deliverability (i.e. predicted GPRs) and dosimetric
characteristics of the QA-optimized plans relative to the original KBP plans were
statistically compared using a two-sided Wilcoxon signed-rank test with a significance
level set to 0.05.
4.3.
4.3.1.

RESULTS
Changes in Predicted QA Outcomes
The predicted GPRs of plans optimized with 25 iterations increased by an

average of 0.30 ± 1.22% (p = 0.42), 1.14 ± 1.25% (p = 0.006), and 1.52 ± 1.27% (p =
0.003) compared to the original plan when using maximum random LG displacements
of 1, 3, and 5 mm respectively. Using 1000 optimization iterations, the predicted GPRs
of the optimized plans increased by an average of 0.32 ± 1.17% (p = 0.31), 1.18 ±
0.99% (p = 0.004), and 1.57 ± 1.08% (p = 0.002) compared to the original plans when
using maximum random LG displacements of 1, 3, and 5 mm, respectively. There were
no significant differences in predicted GPRs of QA-optimized plans when using 25
iterations versus using 1000 iterations for each of the three displacement settings (p =
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0.92, p = 0.35, and p = 0.92 for 1, 3, and 5 mm respectively). Figure 4.2 and Figure 4.3
show changes in predicted GPRs for each patient using different maximum LG
displacements at 25 and 1000 optimization iterations, respectively. The optimization
algorithm runtime was about two minutes using 25 iterations for a given plan and
optimization settings, whereas 1000 iterations resulted in a runtime of about 52 minutes.

Figure 4.2. Changes in predicted GPRs of QA-optimized plans for each patient relative
to the original KBP plans using maximum random LG displacements of 1 (blue), 3
(orange), and 5 (green) mm with 25 optimization iterations. A positive value indicates
the QA-optimized plan has the higher predicted GPR. Note these GPRs were calculated
with a 3%/3mm percent dose-difference/distance-to-agreement gamma criterion using
local normalization.
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Figure 4.3. Changes in predicted GPRs of QA-optimized plans for each patient relative
to the original KBP plans using maximum random LG displacements of 1 (blue), 3
(orange), and 5 (green) mm with 1000 optimization iterations. A positive value indicates
the QA-optimized plan has the higher predicted GPR. Note these GPRs were calculated
with a 3%/3mm percent dose-difference/distance-to-agreement gamma criterion using
local normalization.
4.3.1.1.

Changes in Plan Complexity

Table 4.2 and Table 4.3 show changes in complexity metrics between the QAoptimized plans and the original KBP plans overall all patients when using 25 and 1000
optimization iterations respectively. Overall, the QA-optimized plans showed
significantly (p < 0.05) reduced levels of plan complexity compared to the original plans,
with the magnitude increasing with maximum random LG displacement.
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Table 4.2. Mean ± standard deviations (µ ± !) of the differences in complexity metrics
between QA-optimized KBP plans and the corresponding original KBP plan for 1, 3, and
5 mm maximum random LG displacements. The QA-optimized plans were generated
after 25 iterations.
KBP-QA – KBP
(µ ± !)
Complexity Metric
1 mm
3 mm
5 mm
MU Factor
-2.92 ± 1.04*
-7.93 ± 3.27*
-13.01 ± 5.28*
MCS
0.0034 ± 0.0004*
0.010 ± 0.002*
0.015 ± 0.003*
EM
-0.001 ± 0.0001*
-0.002 ± 0.0004*
-0.004 ± 0.001*
Mean LM (mm/deg)
-0.001 ± 0.002
0.008 ± 0.007*
0.025 ± 0.013*
Mean LG (mm)
0.39 ± 0.02*
1.18 ± 0.07*
1.97 ± 0.12*
Mean Aperture Area
41.80 ± 11.09*
125.61 ± 33.87*
209.30 ± 54.12*
(mm2)
SAS – 50 mm
-0.005 ± 0.002*
-0.018 ±0.006*
-0.029 ± 0.005*
*indicates a statistically significant result with p < 0.05

The optimization algorithm reduced MU factors by 2.92 ± 1.04 (µ ± !; p = 0.001)
and increased the mean LG by 0.39 ± 0.02 mm (p = 0.001) using a maximum LG
displacement of 1 mm. Aperture areas of the QA-optimized plans also increased
significantly, where a 1 mm maximum LG displacement setting resulted in increasing
mean aperture areas by 41.80 ± 11.09 mm2 (p = 0.001) compared to the original plan.
Differences in complexity metrics were negligible when comparing plans using 25 and
1000 optimization iterations.
Table 4.3. Mean ± standard deviations (µ ± !) of the differences in complexity metrics
between QA-optimized KBP plans and the corresponding original KBP plan for 1, 3, and
5 mm maximum random LG displacements. The QA-optimized plans were generated
after 1000 iterations.
KBP-QA – KBP
(µ ± !)
Complexity Metric
1 mm
3 mm
5 mm
MU Factor
-2.93 ± 1.00*
-8.07 ± 3.29*
-12.92 ± 5.66*
MCS
0.0034 ± 0.0004*
0.010 ± 0.002*
0.015 ± 0.003*
EM
-0.001 ± 0.0001*
-0.003 ± 0.0004*
-0.004 ± 0.001*
Mean LM (mm/deg)
-0.001 ± 0.002*
0.008 ± 0.006*
0.026 ± 0.014*
Mean LG (mm)
0.40 ± 0.02*
1.18 ± 0.07*
1.97 ± 0.13*
(table cont’d)
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KBP-QA – KBP
(µ ± !)
3 mm

Complexity Metric
1 mm
Mean Aperture Area
(mm2)
SAS – 50 mm

42.12 ± 10.82*

125.42 ± 32.82*

-0.005 ± 0.002*

-0.017 ± 0.004*

5 mm
208.99 ± 55.42*
-0.028 ± 0.007*

*indicates a statistically significant result with p < 0.05

4.3.2.

Changes in Plan Quality
Figure 4.4 shows the average of the 13 DVHs across the original KBP plan and

the QA-optimized plans with the three different maximum random LG displacements
using 25 iterations. Table 4.4 shows the resulting differences among selected dose
metrics between the QA-optimized plans and the original KBP plan. Deviations in dose
from the original plan generally increased with maximum LG displacement. While
statistical significances were observed for most of the dose metrics for the target and
each of the OARs, the magnitude of the differences were relatively small. For the PTV
dose coverage, significant (p < 0.05) increases were observed for Dmin and Dmean for
each maximum LG displacement. However, the largest average increase that was
observed was minimal, on the order of 1.09 Gy and 0.27 Gy for Dmin and Dmean
respectively when the maximum LG displacement was set at 5 mm. The target dose
distributions also became slightly less conformal and less homogenous as the
maximum LG displacement increased compared to the original KBP plan, where the
conformity index and homogeneity index significantly increased by an average of 0.044
and 0.009, respectively, with the maximum LG displacement set to 5 mm.
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Figure 4.4. Average dose volume histograms over the 13 patients comparing the
original plan (solid black) with the QA-optimized plans using maximum random LG
displacements of 1 (dashed red), 3 (dashdot blue), and 5 (dotted green) mm. These
QA-optimized plans were generated after 25 iterations.
Statistically significant increases in bladder and rectum doses were observed for
each of the dose metrics assessed via Table 4.4. However, the largest average
magnitude of increased Dmean to the bladder and the rectum across all possible
maximum LG displacements was 0.83 Gy and 1.22 Gy, respectively, which correspond
to increases of 3.06% and 4.08% of Dmean. Significant increases in Dmean were also
observed for the left and right femoral heads and penile bulb, with the largest observed
increases being 0.53 Gy, 0.44 Gy and 2.29 Gy on average (representing 2.04%, 1.69%,
and 7.79% of average Dmean values), respectively.
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Table 4.4. Average differences in dose metrics between QA-optimized plans (KBP-QA)
and the original KBP plans for maximum random LG displacements of 1, 3, and 5 mm.
The QA-optimized dose values resulted from plans were generated after 25 iterations.
Mean (KBP-QA – KBP)
Dose Metric
1mm
3mm
5mm
PTV
D2 (cGy)
3.50
32.16*
79.80*
D50 (cGy)
4.77*
8.94
21.93*
D98 (cGy)
0.21
3.90
6.36
Dmin (cGy)
22.89*
65.80*
109.63*
Dmean (cGy)
4.02*
10.97*
26.97*
Dmax (cGy)
-9.12
19.34
87.06*
V95 (%)
0.008
0.04*
0.08*
V98 (%)
-0.01
0.02
0.06
V100 (%)
-0.12
-0.12
-0.12
V107 (%)
0.008
0.12
0.59
HI†
0.0004
0.004*
0.009*
†
CI
0.008*
0.025*
0.044*
Bladder
D10 (cGy)
23.72*
74.63*
129.33*
D30 (cGy)
32.68*
85.22*
147.22*
D50 (cGy)
26.89*
75.44*
123.43*
D65 (cGy)
19.74*
45.56*
76.12*
D80 (cGy)
10.92*
25.78*
41.83*
Dmean (cGy)
18.94*
49.51*
82.78*
Rectum
D10 (cGy)
27.77*
84.26*
140.87*
D30 (cGy)
46.57*
137.14*
226.39*
D50 (cGy)
35.31*
98.69*
158.54*
D65 (cGy)
25.26*
61.61*
102.77*
D80 (cGy)
15.99*
38.91*
62.22*
Dmean (cGy)
25.78*
72.86*
122.35*
Left Femoral
Head
D2 (cGy)
7.26
46.19*
84.64*
Dmax (cGy)
7.82
38.70*
80.30*
Dmean (cGy)
6.22*
30.25*
53.10*
Right Femoral
Head
D2 (cGy)
-1.05
23.53*
47.14*
Dmax (cGy)
-1.79
27.52*
52.74*
Dmean (cGy)
0.82
23.20*
43.89*

(table cont’d)
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Dose Metric
Penile Bulb
Dmean (cGy)

Mean (KBP-QA – KBP)
1mm
3mm
5mm
41.36*

133.93*

229.14*

*indicates a statistically significant result with p < 0.05
†
Homogeneity and conformity indices were calculated according to their International
Commission on Radiation Units & Measurements definitions.

The changes in dose observed in Figure 4.4 and Table 4.4 for QA-optimized
plans with 25 iterations were similar to the dose differences observed for QA-optimized
plans resulting from 1000 iterations, as can be seen in Figure 4.5 and Table 4.5.

Figure 4.5. Average dose volume histograms over the 13 patients comparing the
original plan (solid black) with the QA-optimized plans using maximum random LG
displacements of 1 (dashed red), 3 (dashdot blue), and 5 (dotted green) mm. These
QA-optimized plans were generated after 1000 iterations.
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Again, small, but significant dose differences were observed with increased
maximum LG displacement for these QA-optimized plans resulting from 1000 iterations.
These changes were not noticeably different from those exhibited from the QAoptimized plans resulting from 25 iterations.
Table 4.5. Average differences in dose metrics between QA-optimized plans (KBP-QA)
and the original KBP plans for maximum random LG displacements of 1, 3, and 5 mm.
The QA-optimized dose values resulted from plans were generated after 1000
iterations.
Mean (KBP-QA – KBP)
Dose Metric
1mm
3mm
5mm
PTV
D2 (cGy)
3.21
28.91*
81.46*
D50 (cGy)
4.10*
8.33
22.03*
D98 (cGy)
-0.11
1.72
3.78
Dmin (cGy)
21.94*
67.53*
115.99*
Dmean (cGy)
3.47*
9.79
26.82*
Dmax (cGy)
-11.14
21.46
79.98*
V95 (%)
0.008
0.04*
0.07*
V98 (%)
-0.015
-0.006
0.07
V100 (%)
-0.12
-0.12
-0.12
V107 (%)
0.003
0.09
0.70
HI†
0.0004
0.003*
0.010*
†
CI
0.007*
0.025*
0.045*
Bladder
D10 (cGy)
24.41*
72.70*
131.35*
D30 (cGy)
32.81*
87.39*
142.09*
D50 (cGy)
25.45*
72.33*
129.82*
D65 (cGy)
19.90*
46.69*
75.37*
D80 (cGy)
11.00*
25.05*
41.95*
Dmean (cGy)
18.80*
49.14*
82.92*
Rectum
D10 (cGy)
25.83*
84.41*
138.40*
D30 (cGy)
48.10*
132.83*
231.93*
D50 (cGy)
35.26*
98.53*
166.56*
D65 (cGy)
24.50*
61.43*
101.76*
D80 (cGy)
15.41*
37.45*
63.32*
Dmean (cGy)
25.91*
72.03*
123.69*

(table cont’d)
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Dose Metric
Left Femoral
Head
D2 (cGy)
Dmax (cGy)
Dmean (cGy)
Right Femoral
Head
D2 (cGy)
Dmax (cGy)
Dmean (cGy)
Penile Bulb
Dmean (cGy)

Mean (KBP-QA – KBP)
1mm
3mm
5mm
8.73*
7.33
6.30*

44.04*
51.57*
30.53*

83.00*
84.15*
57.11*

-1.44
0.12
0.53

22.26*
23.49
22.10*

49.77*
64.87*
45.31*

43.38*

132.55*

224.14*

*indicates a statistically significant result with p < 0.05
†
Homogeneity and conformity indices were calculated according to their International
Commission on Radiation Units & Measurements definitions.

Changes in the EUD-based radiobiological metrics TCP and NTCP can be found
in Table 4.6 and Table 4.7 for QA-optimized plans generated after 25 iterations and
1000 iterations, respectively. Significant increases in TCP were observed across each
maximum LG displacement setting. Statistically significant increases in NTCP were
observed for the bladder, rectum, and femoral heads, although the magnitudes of each
were less than 0.22%, on average.
Table 4.6. Summary of mean differences (∆) in the radiobiological metrics based on
equivalent uniform doses: tumor control probability (TCP) and normal tissue
complication probability (NTCP). Here, ∆ reflects the difference between the QAoptimized values and the original values. Specifically, a positive ∆TCP (or ∆NTCP)
indicates the QA-optimized plan had a higher TCP (or NTCP) value than the original
plan. These QA-optimized plans were generated after 25 iterations.
∆NTCP (%)
Max LG
∆TCP (%)
Displacement
Bladder Rectum Left Femur Right Femur
(10-2)
(mm)
(10-4)
(10-1)
(10-7)
(10-8)
1
0.6*
2.2*
0.2
0.1
-0.5
3
2.4*
4.2*
1.1*
0.7*
2.1*
5
4.7*
8.0*
2.2*
1.3*
5.6*
*indicates a statistically significant result with p < 0.05
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The magnitudes in the changes observed for these radiobiological metrics were
similar regardless of the number of iterations used to generate the QA-optimized plans.
Table 4.7. Summary of differences (∆) in the radiobiological metrics based on equivalent
uniform doses: tumor control probability (TCP) and normal tissue complication
probability (NTCP). Here, ∆ reflects the difference between the QA-optimized values
and the original values. Specifically, a positive ∆TCP (or ∆NTCP) indicates the QAoptimized plan had a higher TCP (or NTCP) value than the original plan. These QAoptimized plans were generated after 1000 iterations.
∆NTCP (%)
Max LG
∆TCP (%)
Displacement
Bladder Rectum Left Femur Right Femur
(10-2)
(mm)
(10-4)
(10-1)
(10-7)
(10-8)
1
0.6*
2.0*
0.2
3
2.1*
4.6*
1.1*
5
5.1*
7.9*
2.2*
*indicates a statistically significant result with p < 0.05

4.4.

0.1
0.7*
1.5*

0.5
2.3*
5.9*

DISCUSSION
This study explored the idea of integrating the prediction of VMAT QA outcomes

into the plan design stage by using a machine learning model as a feedback
mechanism within a heuristic algorithm for adjusting mechanical parameters of
treatment plans towards increasing their predicted deliverability without degrading their
dosimetric quality. Specifically, an SVM model based on QA measurements of 500
previous VMAT treatment plans was implemented into the plan optimization workflow.
The algorithm selects plan features (deemed to be important for accurately predicting
QA outcomes using the SVM model) and randomly modifies them in searching for a
solution that maximally increases predicted deliverability. Using 13 previous KBPguided VMAT plans for purposes of demonstrating feasibility, the QA-optimization
algorithm was found to yield statistically significant increases in predicted GPRs and
reductions in plan complexity, while minimally altering the plan quality in terms of
dosimetric and radiobiological metrics. Although the magnitude of each of these
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changes increased with maximum random LG displacement, a 3 mm maximum
displacement and 25 iterations yielded QA-optimized plans with a 1.14 ± 1.25% (µ ± !;
p = 0.006) increase in predicted GPRs and negligible increases (largest average
increase of 0.1% among bladder, rectum, and femoral heads) in OAR NTCPs, although
these increases were statistically significant (p < 0.05).
To our knowledge, this is the first study exploring the feasibility of a planning and
quality assurance framework that directly integrates predicted QA outcomes into the
plan design process. Previous investigators have researched the efficacy of using
individual complexity penalties to improve the deliverability of treatment plans. For
instance, Younge et al. found it was possible to improve dose delivery accuracy by
penalizing plans with complex aperture shapes via their “edge” metric without resulting
in substantial changes to the dose distribution quality.112 While many different
complexity metrics and mechanical plan features have been studied for quantifying and
predicting pre-treatment QA results, few significant relationships have been found
between them for VMAT QA.144,165 In other words, penalizing plan complexity without
direct knowledge of how the associated changes in mechanical plan parameters impact
resulting QA measurements is not guaranteed to result in improved dose delivery
accuracy. This has led to assessing the capability of machine learning models of
accurately predicting QA outcomes from a large array of different plan complexity
metrics.95-97,99,101,122,166 The present work advances and builds upon these previous
works by employing one such machine learning model for purposes of developing a
planning QA tool for improving predicted delivery accuracy as defined by GPRs from
QA measurements.
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The novel and innovative component of this study is the implementation of such
a machine learning model directly into the planning optimization process, in effect
including predicted QA outcomes as an additional, plan-specific objective function. QAbased optimization has the potential to improve overall plan quality without
compromising the deliverability of the plan, in addition to producing efficiency gains in
the treatment planning optimization and QA process. As opposed to previous studies
that apply penalties based on single complexity or plan features, QA-based optimization
modifies a group of aperture-based complexity metrics selected specifically to improve
predicted GPRs. This inserts QA-specific endpoints into the plan optimization process,
thereby providing a priori information to the planner regarding a plan’s likely QA
outcome. Also, given the recent recommendations by TG-218 of stricter tolerance and
action levels in evaluating patient-specific QA, QA-based optimization could help
maintain the dosimetric quality of treatment plans while still meeting these QA
guidelines.114 In a more general sense, QA-based optimization represents a step
towards creating the best possible plan and delivery for each patient.
It is important to note the limitations of utilizing radiobiological metrics for
purposes of predicting clinical outcomes. While the goal for every radiation therapy
treatment is to simultaneously maximize tumor cell death and minimize risk of normal
tissue complications, treatment plans are typically evaluated by physical dose-volume
metrics, which are merely a surrogate for these biological endpoints. This has led to an
effort to integrate biologically relevant metrics into the treatment planning design and
evaluation process.167,168 Even though several commercial TPSs have begun to
incorporate biologically based models, predictive NTCP and TCP models have had
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limited clinical presence to date due to questions of reliability and uncertainties.
Specifically, variations in model parameter estimates (e.g. {, d•~ , etc.) have been
shown to yield different radiobiological predictions.169-171 These uncertainties are largely
due to a lack of satisfactory datasets for confidently establishing the correlation between
these predictive biological metrics and realized clinical outcomes.172 Acknowledging
these deficiencies in using NTCP and TCP models for accurately predicting absolute
biological metrics for plan evaluation, these models’ ability to correctly capture volume
effects and general radiobiological trends can still prove useful for a relative comparison
in plan quality. This serves as the rationale for implementing the phenomenological,
EUD-based models of NTCP and TCP in this study for evaluating differences in plan
quality between QA-optimized plans and their original counterparts. Further, while
statistically significant differences were observed in TCP and several OAR NTCP values
among QA-optimized plans, the magnitude of these differences (maximum difference of
0.22%; Table 4.6 and Table 4.7) can be considered small within the context of the
uncertainties associated with these radiobiological models in general.
This study had other limitations. One practical limitation was the inability to
integrate QA-based optimization directly into an existing TPS optimization and dose
calculation framework. Several options were explored and considered before deciding
to evaluate feasibility via the present workflow. Integration of QA-based optimization
within an existing TPS would facilitate a more efficient and comprehensive investigation
into the tradeoff between increased levels of predicted QA outcomes and corresponding
changes in dosimetric plan quality. This would enable a future study with a larger cohort
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of initial testing plans as well. Nonetheless, the present results demonstrate the viability
of implementing a QA-based optimization into an existing inverse planning workflow.
The results from this work show that in general, predicted GPRs increased with
larger maximum LG displacement settings. This validates the previous feature analysis
study indicating LGs and small apertures as reasonable surrogates for adjusting the
aperture-based complexity features used to predict GPRs by the SVM model. Further,
larger maximum LG displacements tended to result in decreased plan complexity, but
increased changes in dose distributions when compared to the original plans. Among
the different magnitudes in adjustments made to the complexity features used by the
SVM, the 3 mm LG setting seems to be a suitable selection for future integration and
testing within a commercially available TPS as it provided the best trade-off in
maximizing predicted GPRs and minimizing changes in dosimetric quality of the plans.
While further investigation may reveal a more optimal maximum LG displacement
setting, the present results suggest that the improvements in the aforementioned tradeoff would likely be clinically negligible.
Another limitation of this study was the inherent accuracy of the machine learning
model used to inform the heuristic search. The SVM model implemented in this work
yielded a testing mean absolute error of 3.75% for predicting VMAT GPRs, which is on
the order of the improvements in predicted GPRs achieved by incorporating the SVM
model into the optimization process. However, a significant reduction in overall plan
complexity was observed in the QA-optimized plans relative their original KBP plans
(Table 4.2 and Table 4.3). Additionally, preliminary QA measurements of these
optimized plans seem to agree with the differences in predicted QA yielded from the
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SVM model, although a more thorough and complete measurement assessment is
needed for verification.
While this study focused on solely prostate treatment plans, it would be
interesting to investigate the potential impact of this optimization workflow for other,
more complex treatment sites, such as head and neck cancers. It is possible the
differences in predicted QA outcomes would be more pronounced for treatment sites
requiring more complex MLC leaf sequences and larger, more irregularly shaped
apertures than prostate cases. However, given a significant increase in predicted QA
was observed for these prostate plans without substantially degrading dosimetric quality
provided by KBP-guidance is an indication of the potential clinical utility and applicability
for any treatment site and inverse optimization planning environment.
The proposed QA-based optimization framework for improving plan deliverability,
when paired with a data-driven KBP method, represents a step forward towards a
planning workflow integrating both dose- and QA-based objectives for designing a
treatment plan with the best composite dosimetric quality and delivery accuracy. The
more immediate clinical impact of this framework would be an increase in efficiency, as
the number and likelihood of plans failing QA would decrease and could be predicted
prior to measurement. Also, an important and novel consequence of this work is the
ability to establish the direct connection between global plan complexity mitigation tools
within existing TPSs and corresponding QA outcomes during the planning process.
4.5.

CONCLUSION
While current TPSs have simple global penalties aiming to reduce complexity

and control the likelihood of a plan failing QA measurements, these penalties are
surrogates for QA outcomes; any potential impact on QA outcomes would be unknown
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until measurement. This study is the first to investigate the feasibility of a planning tool
that incorporates a machine learning model into the optimization of VMAT plans. An
SVM model, previously trained and tested to predict VMAT GPRs based on an array of
plan complexity features, was used to inform a heuristic algorithm for modifying plan
parameters with the aim of increasing the predicted GPR. Significant increases in
predicted GRPs were observed over 13 QA-optimized plans compared to original
reference plans without substantially compromising the dosimetric quality of the plan.
Therefore, this study has shown the feasibility of a QA-based optimization routine – with
a maximum LG displacement of 3 mm and just 25 iterations – for increasing predicted
plan deliverability without impacting dosimetric nor radiobiological plan quality. This
novel QA-based optimization could be a useful addition to inverse planning workflow to
improve both the overall quality and deliverability of clinical treatment plans.
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5. CONCLUSIONS
5.1.

SUMMARY OF FINDINGS
The overall goals of this dissertation were threefold: to evaluate differences in

dose, complexity, and QA outcomes between reference clinical plans and those
designed with an in-house KBP technique (Chapter 2); to develop and compare
machine learning models for predicting VMAT QA outcomes based on an array of plan
complexity features (Chapter 3); and to assess the feasibility of optimizing plan
deliverability of VMAT treatment plans using a machine learning model to predict QA
outcomes (Chapter 4).
Thirty-one prostate patients previously treated with VMAT were re-planned with
an in-house KBP method based on the overlap volume histogram. In addition to
evaluating differences in dose, differences in VMAT plan complexity were quantified via
normalized MUs, modulation complexity scores, the edge metric, and average leaf
travel per degree of gantry rotation (i.e. leaf motion) for both the reference clinical plans
and KBP plans. Each set of plans for each patient was delivered to the same diodearray and GPRs were utilized to quantify the level of agreement between the computed
and measured dose distributions. While KBP plans achieved noticeable gains in bladder
and rectum dose – with average reductions of 6.4 Gy (p < 0.001) and 8.2 Gy (p < 0.001)
in mean bladder and rectum dose compared to reference plans – they were found to be
significantly more complex than reference plans. On average, KBP plans required 143 ±
93 more MUs (p < 0.001), had reduced MCS values of 18% (p < 0.001; indicating
increased complexity), had 40% higher EM values (p < 0.001), and 47% higher LM (p <
0.001) compared to reference plans. Further, KBP plans were also more susceptible to
QA measurement errors. For gamma criteria with global normalization, KBP plans on
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average had gamma passing rates that were 1.1, 1.6, 3.8, and 7.8 percentage points
lower than reference plans at the 3%/3mm (p = 0.009), 3%/2mm (p = 0.003), 2%/2mm
(p = 0.002), and 1%/1mm (p < 0.001) criteria respectively.
These observed differences in plan complexity and deliverability between KBP
and reference clinical plans served as motivation for further investigating the
relationship between complexity features and QA outcomes through the use of machine
learning models. This was established using a dataset of 500 VMAT treatment plans
and diode-array QA measurements, upon which an array of machine learning models
was trained. GPRs were computed using a 3%/3mm percent dose-difference and
distance-to-agreement gamma criterion with local normalization. 241 complexity metrics
and plan parameters were extracted from each treatment plan and their relative
importance for accurately predicting GPRs was assessed and compared using feature
selection methods via forests of Extra-Trees, mutual information, and linear regression.
Hyperparameters of different machine learning models – which included linear models,
support vector machines (SVMs), tree-based models, and neural networks – were tuned
using cross-validation on the training data (80%/20% training/testing split). While
features were weakly correlated with GPRs in general, with the small aperture score
(SAS) at 50 mm having the largest absolute Pearson correlation coefficient (0.38; p <
0.001), the SVM model, trained using the 100 most important features selected using
the linear regression method, yielded the lowest cross-validation testing mean absolute
error of 3.75%. While not as accurate as previously published models designed to
predict GPRs for fixed-gantry IMRT plans (e.g. Valdes et al. reported being able to
predict GPRs within 3%), the SVM model in this study provided a significant
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improvement in performance compared to “random guessing” for predicting VMAT QA.
Furthermore, its ability to capture the general relationship between plan complexity and
resulting QA outcomes was determined to be sufficient for utilization in the subsequent
objective of this work: to explore the feasibility of developing a QA-based optimization
framework for inverse planning workflows.
A heuristic optimization framework was proposed for directly maximizing
predicted QA outcomes of plans without degrading the quality of the plan’s dose
distribution using the aforementioned SVM model. Thirteen of the prostate VMAT plans
designed with an in-house KBP system from Chapter 2 were used to assess the
feasibility of this framework. An algorithm was devised by utilizing the SVM model to
guide iterative modification of mechanical treatment features most commonly
associated with suboptimal GPRs. Specifically, leaf gaps (LGs) less than 5 cm were
widened by random amounts, which impacts several complexity features such as small
aperture scores and aperture area uniformity. The original 13 plans were optimized with
this QA-based algorithm using maximum LG displacements of 1, 3, and 5 mm before
corresponding changes in predicted GPRs and dose were assessed. Predicted GPRs
increased by an average of 0.30 ± 1.22% (p = 0.42), 1.14 ± 1.25% (p = 0.006), and 1.52
± 1.27% (p =0.003) after QA-based optimization for 1, 3, and 5 mm maximum random
LG displacements, respectively. Differences in dose were minimal, resulting in clinically
negligible changes in tumor control probability (maximum increase = 0.05%) and normal
tissue complication probability (maximum decrease = 0.2% among bladder, rectum, and
femoral heads).
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The hypotheses of this study were (1) that KBP-guided plans would result in
significantly higher complexity and reduced gamma passing rates (p < 0.05) compared
to reference clinical plans and (2) that a machine learning model designed to predict
VMAT QA gamma passing rates can be used within an in-house optimization workflow
to increase predicted delivery accuracy without compromising KBP plan quality. To this
end, the results of from this study support the first hypothesis as KBP plans were
observed to have significantly increased levels of complexity and QA errors. As for the
second hypothesis, the feasibility of using a QA-based optimization framework to
improve predicted plan deliverability was demonstrated in this study, with improved
levels of predicted GPRs without sacrificing the dose gains provided by the KBP
technique.
5.2.

LIMITATIONS
There were several limitations of this work. The use of a diode-array, while

shown to be a viable measurement device for performing VMAT QA,140-142 lacks the
spatial resolution advantages that can be found in other dosimeters such as film. Planar
diode-arrays have also been shown to be overresponsive to lateral beam angles, which
could have impacted measured GPRs in this study.139,140 A more complete
characterization of the sources of error would be a useful future avenue of research.
Another limitation of this study was the inability to integrate and test the QAbased optimization concept directly within an existing TPS. This restricted the extent
and scope of possible testing, as performing plan modifications external to a TPS before
importing the modified plans to compute dose and evaluate changes in the resulting
dose distribution is inefficient for testing many different patients and combinations of
optimization settings. Still, the methods described in this work demonstrate feasibility of
96

such a method and the potential clinical advantages that warrant further TPS
integration.
As mentioned in Chapter 4.4, the accuracy of the SVM model used within the
QA-based optimization algorithm was another limitation of this study. The testing MAE
of 3.75% for predicting VMAT GPRs was larger than any of the average increases in
predicted GPRs across the 13 patient plans that were tested via the QA-based
optimization algorithm. However, significant reductions in overall plan complexities were
observed for the modified plans, which aligns with what would be expected. Also,
preliminary QA measurements of a sample of QA-optimized plans seem to support the
predicted differences in QA outcomes from the SVM model, although a more complete
validation study is needed.
5.3.

FUTURE WORK
A logical next progression for this project would be to explore how these results

generalize to other, generally more complicated treatment sites such as the head-andneck and to other combinations of technologies (e.g. KBP implementation, TPS,
treatment machine, and measurement device). An important note for this study is that
these results were observed for the specific dataset and clinical tools used in the
experimental methods. These results, combined with those from previous works,
indicate there may be some variation present when considering different treatment sites
and technologies.
It would also be worthwhile to investigate and characterize the specific sources of
error that led to the observed decreases in KBP QA outcomes relative to the reference
clinical plans. Although sources of error in IMRT planning and delivery have been
studied extensively, it would be interesting to assess the primary sources of error within
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the context of the in-house KBP method used in this study. Along the same lines, it
would be useful to investigate a machine learning model that can predict multiple
classes of delivery accuracy metrics that may be more clinically relevant than the GPR.
For instance, being able to predict measured dose differences along the central axis or
the mean gamma value, when combined with GPRs, could yield more useful indications
for clinically relevant patient dose errors.173
In preparation for these tools to be implemented clinically, future work would
need to be performed to further validate the potential clinical benefits of an in-house
KBP method and QA-based optimization framework. One or several radiation
oncologists would need to provide feedback on the quality of the KBP-guided plans to
ensure their clinical acceptability. Further testing of the QA-based optimization algorithm
is also needed to verify its clinical utility, which would involve a larger number of patients
with varying treatment sites. This testing would ideally be performed directly within an
existing TPS. This integration with commercial TPSs represents an important and
necessary next step towards realizing a clinically useful tool. Discussions were held with
an interested vendor in the development of this work regarding the possibility of
implementing and testing this QA-based optimization within their existing TPS
framework, which did not materialize due to timeline restrictions of the project. However,
it should be possible to integrate the present QA-based optimization framework within
any existing TPS inverse planning process by adding a predicted GPRs objective to the
composite objective function. This TPS integration would also facilitate further fruitful
investigations, such as the assessment of other optimization algorithms for modifying
the mechanical parameters that may be more efficient and lead to even larger
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improvements in predicted GPRs. Lastly, verification measurements should be
performed to confirm the QA predictions made by the machine learning algorithm.
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APPENDIX C.
C.1.

SUPPLEMENTARY MATERIAL

CHAPTER 2

Local

Global

Table C.1. Statistical summary of the differences in coefficients of variation (COV) of
inter-delivery measurements at each gamma criteria between reference and KBP plans
over the three separate measurements.
Gamma
Criteria

Reference Plans
COV
(@ ± ! x 10-2)

KBP Plans
COV
(@ ± ! x 10-2)

3%/3mm

0.3 ± 0.3

0.5 ± 0.6

0.005*

3%/2mm

0.4 ± 0.4

0.8 ± 0.7

0.001*

2%/2mm

0.8 ± 0.5

1.8 ± 1.4

< 0.001*

1%/1mm

3.1 ± 2.1

4.8 ± 3.4

0.005*

3%/3mm

0.9 ± 0.6

1.3 ± 1.0

0.02*

2%/2mm

1.3 ± 1.0

2.1 ± 1.6

0.004*

1%/1mm

2.8 ± 1.9

4.2 ± 2.4

0.003*

t-test
p-value

*Indicates a statistically significant result of p < 0.05

Figure C.1. Average DVHs comparing original clinical plans (solid) to the reconstructed
reference clinical plans (dashed) for the 31 patients of each labelled planning structure
(a-f). The standard error of the means is also included as filled bands with solid
(original) or dashed (reference) edge lines. Note that doses were normalized so that
95% of the PTV received 76 Gy.
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Figure C.2. Distributions of the 31 paired differences between KBP and reference plans
for planned MUs (a), MCS values (b), EM values (c), and LM (d). Positive values in
each complexity metric plot indicate the KBP value was larger (i.e. more complex) than
the corresponding reference plan value. Note in (b), 1 – MCS values were plotted so
that higher values indicate higher complexity in each plot. Horizontal black lines within
each box indicate distribution medians; notches indicate the 95% confidence intervals
around each median, grey circles indicate the distribution means; whiskers indicate the
range of data points lying within the 1.5 times the interquartile range and crosses
indicate points outside this range.
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Figure C.3. Distributions of differences in gamma passing rates between reference
plans and KBP plans at each gamma index criteria calculated with both global (left) and
local (right) normalization. Negative values indicate the KBP plan had a lower gamma
passing rate. Same boxplot characteristics from the Figure C.2 caption apply here.

Figure C.4. Correlation between increased plan complexity and improvement in plan
quality. Differences between KBP and reference plans are shown, where positive y
values indicate increased KBP plan complexity and negative x values indicate improved
or lower bladder (a, c, e, g) or rectum dose (b, d, f, h).
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C.2.

CHAPTER 3

Table C.2. Hyperparameters of the models listed in Table 3.5 that were tuned with cross-validated searches.
Min
Max
Number of Learning
Algorithm
!
" Kernel
C
#
$
Samples Loss
Subsample
Depth
Estimators
Rate
per Leaf
Elastic
0.594 1
Net
1
SVM
- RBF 6.407 0.094
&!"#$%&"' × ( (
Decision
3
17
MAE
Tree
Random
12
4
MSE
124
Forest
AdaBoost
91
1.311
Gradient
14
6
616
0.007
0.444
Boosting
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Hyperparameter Tuning
The following describes the specifics of the cross-validated searches carried out
for each model to determine the optimal hyperparameters reported in the main text.
C.2.1.1.

Elastic Net

The Elastic Net hyperparameters ! and " were optimized by a 10-fold cross
validated grid-search over specified parameter spaces. The optimal ! was determined
from 100 uniformly sampled values ranging from 0.005 to 0.25, while the optimal " was
determined from 10 uniformly sampled values ranging from 0 to 1.
C.2.1.2.

Support Vector Machine

Hyperparameters for SVMs were optimized with a 5-fold cross-validated
randomized search with 250 iterations. Table C.3 lists the defined parameter space over
which the randomized search was conducted.
Table C.3. SVM parameter space ranges over which optimal parameter values were
randomly searched with 5-fold cross-validation.
SVM Parameter
Defined Search Domain
Linear, Polynomial, Gaussian RBF,
Kernel
Sigmoid
Degree (Polynomial kernel only)
1-11
1000 equally spaced points between
C
0.001 and 100
1000 equally spaced points between
#
0.001 and 1.5
1
1
$ (for Polynomial, Gaussian RBF, and
,
Sigmoid kernels)
&!"#$%&"' &!"#$%&"' × ) (
C.2.1.3.

Decision Tree

The Decision Tree hyperparameters optimized in this study were the maximum
tree depth, the minimum number of samples required at each node, and the loss
function to measure the quality of a split. These hyperparameters were tuned with a 10107

fold cross-validated randomized search of 100 iterations over the specified parameter
space. The range of searched values were 1 to 20 levels for the maximum tree depth
parameter, 1 to 20 samples for the minimum number of samples required at each node
parameter, and either MSE or mean absolute error (MAE) for the loss function.
C.2.1.4.

Random Forest

The same tree-growing hyperparameters and their associated ranges of values
given in C.2.1.3 were similarly optimized for Random Forests using a 10-fold crossvalidated randomized search over 100 iterations. The number of trees in each forest
was also optimized in this randomized search, where models could have anywhere
between 10 and 1000 estimators.
C.2.1.5.

AdaBoost

The AdaBoost-specific hyperparameters were optimized via a 10-fold crossvalidated randomized search with 100 iterations. The parameters tuned in this study
were the maximum number of estimators at which boosting was terminated (values
ranged from 10 to 1000) and learning rate (values ranged from 0 to 2), which scales the
contribution of each regressor.
C.2.1.6.

Gradient Boosting

The optimal Gradient Boosting parameters were selected via a 10-fold crossvalidated randomized search with 100 iterations over the defined parameter space. The
parameters tuned in this study were the maximum number of estimators (ranging from
10 to 1000), learning rate (ranging from 10-5 to 1), the fraction of training samples to be
used for fitting the individual base predictors (ranging from 10-5 to 1), the maximum tree
depth (ranging from 1 to 20), and the minimum number of samples required to split an
internal node (ranging from 1 to 20).
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C.2.1.7.

Artificial Neural Network

For ANN hyperparameter optimization, a randomized search of 194 iterations
over the given parameter space (Table C.4) was performed for each of the 21
combinations of feature sets using the open-source package Talos
(http://github.com/autonomio/talos). Each of the 21 models was trained using 10-fold
cross-validation.
Table C.4. ANN hyperparameter space defined for optimization using the Talos
package.
Talos-specific hyperparameter
Parameter space
Learning Rate
0.001 to 1
Number of neurons in first layer 5 to 50
Batch Size
32 to 125
Number of hidden layers
1 to 10
Topology Shapes†
‘brick’, ‘triangle’, ‘funnel’
Epochs
50 to 500
Dropout
0 to 0.5
Optimizer
Adam, SGD, Nadam
Losses
MSE, MAE
Hidden layers activation function Sigmoid, tanh, relu, linear
Output layer activation function
Sigmoid, tanh, relu, linear
†

Topology shapes are package-specific names where ‘brick’ assigns the same number of neurons in each
layer, ‘triangle’ decreases the number of neurons by a constant number with each layer so that the
shape resembles a triangle, and ‘funnel’ decreases the number of neurons by floor of the difference
between the specified number of neurons in the first layer and last layer divided by the number of
desired hidden layers, resulting in a funnel shape.
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APPENDIX D.

COMPLEXITY METRICS

Below is the list of complexity features used in this work along with their
definitions and works from which they were derived, if applicable.
Number
1.

Name
AA moments,
weighted†

2.

AA moments†

3.

AA, average
AA, average
weighted

4.
5.

AA, weighted

6.

AP moments,
weighted†

7.

AP moments†

8.

AP, average
AP, average
weighted

9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.

AP, weighted
Aperture Area
(AA)
Aperture
Perimeter (AP)

Definition
Moments of AA weighted by CP MU
distribution over all CPs in plan
Moments of AA distribution over all
CPs in plan
Average AA over all CPs in plan
Average AA weighted by CP MU over
all CPs in plan
Sum of AAs weighted by CP MU over
all CPs in plan
Moments of AP weighted by CP MU
distribution over all CPs in plan
Moments of AP distribution over all
CPs in plan
Average AP over all CPs in plan
Average AP weighted by CP MU over
all CPs in plan
Sum of APs weighted by CP MU over
all CPs in plan

Reference(s)
143

143
143
143

143

143

143
143
143

143

Sum of AAs over all CPs in plan

143

Sum of APs over all CPs in plan

143

Sum of degrees of gantry rotation in
plan
Closed Leaf Score Ratio of closed leaf pairs to all leaf
(CLS)
pairs weighted by CP MU
Collimator angle, Collimator angle averaged over each
average
beam
Ratio of number of leaf pairs where
Cross-Axis Score one leaf crosses central axis over total
(CAS)
number of in-field leaf pairs weighted
by CP MU
Ratio of MLC side lengths and
Edge Metric (EM)
aperture perimeter
FAOC moments, Moments of FAOC weighted by CP
weighted†*
MU distribution over all CPs in plan
Moments of FAOC distribution over all
FAOC moments†*
CPs in plan
Arc length

110

144

95

144

112

95

95

Number
20.
21.

Name
FAOC, average
weighted*
Fractional Area
Outside of Circle
(FAOC), average*

22.

Leaf Gap (LG)

23.

Leaf Motion (LM)

24.

Leaf Travel (LT)

25.

LG moments,
weighted†

26.

LG moments†

27.
28.

LG, average
weighted
LM moments,
weighted†

29.

LM moments†

30.

LM, weighted
LT moments,
weighted†

31.
32.
33.
34.
35.
36.
37.

LT moments†
LT, average
weighted
Machine
MLC – agility
MLC – i2
Modulation
Complexity Score
(MCS)

38.

MU factor

39.

Number of arcs
PI moments,
weighted†

40.
41.

PI moments†

42.

PI, average

Definition
Reference(s)
Average FAOC weighted by CP MU
95
over all CPs
Average fraction of AA outside a circle
95
of radius r centered at isocenter over
all CPs
Average LG of each leaf pair over all
95
CPs in plan
Average leaf travel per degree of
121
gantry rotation per leaf, averaged over
all CPs in plan
113 121
Average total leaf travel per leaf
,
Moments of LG weighted by CP MU
95
distribution over all leaf pairs in each
CP in plan
Moments of LG distribution over all leaf
95
pairs in each CP in plan
Average LG of each leaf pair weighted
95
by CP MU over all CPs in plan
Moments of average LM distribution of
121
leaves weighted by CP MU
Moments of average LM distribution of
121
leaves
121
LM weighted by CP MU
Moments of total leaf travel distribution
113 121
,
of leaves weighted by CP MU
Moments of total leaf travel distribution
113 121
,
of leaves
LT weighted by CP MU
Name of treatment machine
Binary, yes or no
Binary, yes or no
Product of aperture area variability,
leaf sequence variability, and control
point (CP) weight
Total planned MUs divided by total
fractional dose to the specification
point i.e. iso

113

, 121

95
95
95

120

, 113

143

95

Moments of AI weighted by CP MU
distribution over all CPs in plan
Moments of AI distribution over all CPs
in plan
Average AI over all CPs in plan

111

143

143
143

Number
43.

Name
PI, average
weighted

44.

PI, weighted

45.

Plan irregularity
(PI)

46.

Plan modulation
(PM)

47.

Small Aperture
Scores (SAS)‡

48.

SAS, maximum‡

49.
50.
51.
52.
53.

Y jaw position,
average
Y1/Y2 jaw motion,
average weighted
Y1/Y2 jaw motion,
average†
Y1/Y2 jaw
position, average
Y1/Y2 jaw travel

Definition
Average AI weighted by plan MU over
all CPs in plan
Sum of AI values weighted by CP MU
over all CPs in plan
Computed aperture irregularity (AI) as

Reference(s)

non-circularity of each aperture: +,∙));
sum of AI values over all CPs in plan
Computed as the weighted sum of
each beam’s modulation value: *+. =

143

)* !

∑ 01 ∙))

143

143

#
"#
"#
1 − 01
; where .(00.4 )
∙1()) )

143

is the union area of all apertures of
beam i
Ratio of leaf gaps smaller than given
distance r weighted by CP MU
Maximum of SAS scores over all CPs
in plan

144

Average of Y1 and Y2 positions

95

"

"#

Average Y1/Y2 jaw motion weighted
by CP MU
Average jaw travel per degree of
gantry rotation of each Y1/Y2 jaw

144

95

95

Averaged over all CPs

95

Total Y1/Y2 jaw travel over plan

95

†the k = 2nd, 3rd, 4th, and 5th moments were used in this study
‡distance criteria of r = 5, 10, 15, 20, 25, 30, 35, 40, 45, and 50 mm were used in this study
*circles of radii = 25, 50, 75, 100, 125, 150, 175, and 200 mm were used in this study
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